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Testing of buffy coat platelet concentrate pathogen inactivation by 
Intercept double-dose system in North Estonia Medical Centre´s 
Blood Centre 
The aim of this thesis was to develop a method for production of buffy coat platelet 
concentrates suitable for use with Intercept platelet processing set with dual-storage 
containers and to assess the conformity of pathogen inactivated platelet products with the 
required and recommended quality parameters. 
The validation of platelet concentrate production using six buffy coats proved the conformity 
to requirements for platelet content, volume, plasma content, and red blood cell concentration 
set for platelet concentrates suitable to be processed with Intercept system. After processing 
with Intercept system, the platelet and white blood cell content were assessed to be 
appropriate. A little concern was the lower than recommended amount of volume per platelet 
content in about half of the products, but as those were the units containing about average or 
higher platelet content and storage analysis showed good platelet recovery and normal pH 
values at the end of shelf-life, the overall results for volume were also considered to be 
acceptable. Both the platelet concentrate production and Intercept treatment process were 
evaluated to be efficient in terms of platelet recovery. 
Keywords: platelets, blood processing, blood safety, pathogen inactivation, Intercept 
CERCS code: T115 Medical technology 
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BC trombotsüütide kontsentraadi patogeeninaktiveerimise 
katsetamine Intercept kahe säilituskoti süsteemiga Põhja-Eesti 
Regionaalhaigla Verekeskuses 
Antud magistritöö eesmärgiks oli välja töötada tootmismeetod, mis võimaldaks valmistada 
BC trombotsüütide kontsentraate, mis sobiksid töötlemiseks kahe säilituskotiga Intercept 
trombotsüütide patogeeninaktiveerimise süsteemiga ning vastaksid töötlemise järgselt 
kohustuslikele ning soovituslikele kvaliteedinõuetele. 
Trombotsüütide kontsentraadi valmistamise valideerimisega tõestati, et saadud tooted 
vastavad patogeeninaktiveerimissüsteemi tootja poolt kehtestatud trombotsüütide sisalduse, 
mahu, plasma sisalduse ja erütrotsüütide kontsentratsiooni kriteeriumitele ning sobivad seega 
töötlemiseks Intercept süsteemiga. Intercept patogeeninaktiveerimise süsteemiga töötlemise 
järgselt hinnati toote trombotsüütide ja leukotsüütide sisaldus sobivaks. Kuigi kõigis toodetes 
maht ei vastanud soovitatud nõuetele, hinnati see siiski sobivaks kuna antud toodetes oli 
trombotsüütide sisaldus pigem kõrgem kui keskmiselt ning säilivusanalüüsid näitasid häid 
tulemusi nii trombotsüütide sisalduse kui ka pH suhtes. Nii trombotsüütide kontsentraadi 
tootmise kui ka Intercept süsteemiga töötlemise protsess hinnati efektiivseks trombotsüütide 
saagise koha pealt. 
Märksõnad: trombotsüüdid, vere töötlemine, vereohutus, patogeeninaktiveerimine, Intercept 
CERCS kood: T115 Meditsiinitehnika 
  
4 
 
Table of contents 
Abbreviations .......................................................................................................................................... 6 
1. Introduction ................................................................................................................................... 7 
2. Literature overview ....................................................................................................................... 8 
2.1 Composition of blood ............................................................................................................ 8 
2.2 Blood collection and processing ........................................................................................... 9 
2.2.1 Blood collection ............................................................................................................ 10 
2.2.2 From whole blood to blood components .................................................................... 11 
2.2.3 Storage of blood components ...................................................................................... 13 
2.3 Clinical use of platelet concentrates ................................................................................... 13 
2.4 Blood transfusion safety ...................................................................................................... 14 
2.4.1 Transfusion-transmissible infections ......................................................................... 15 
2.4.2 Bacterial contamination .............................................................................................. 18 
2.5 Pathogen inactivation technology ...................................................................................... 21 
2.5.1 Intercept system for platelets ..................................................................................... 22 
2.5.2 Mirasol system for platelets ........................................................................................ 23 
2.5.3 Theraflex system for platelets ..................................................................................... 24 
2.5.4 Concerns regarding pathogen inactivation technology ............................................ 24 
3. Experimental ................................................................................................................................ 26 
3.1 Production- and measuring devices ................................................................................... 26 
3.2 Materials and aids in production process ......................................................................... 27 
3.3 Weight of tare ...................................................................................................................... 27 
3.4 Buffy coat production ......................................................................................................... 27 
3.5 Validation of 6BC platelet concentrate production .......................................................... 28 
3.6 Validation of 6BC platelet concentrate pathogen inactivation by Intercept platelet 
processing set with dual storage containers .................................................................................. 29 
3.7 Production after validations ............................................................................................... 30 
3.8 Collected data and calculations .......................................................................................... 30 
3.8.1 Collected data .............................................................................................................. 30 
3.8.2 Calculations .................................................................................................................. 31 
3.8.3 Estimation of measurement uncertainties ................................................................. 32 
4. Results and Discussion ................................................................................................................ 34 
4.1 Buffy coat adjustment ......................................................................................................... 34 
4.2 6BC platelet concentrate production ................................................................................. 35 
5 
 
4.3 Intercept treatment process ................................................................................................ 36 
4.4 Production planning ............................................................................................................ 39 
5. Summary ...................................................................................................................................... 40 
6. Kokkuvõte .................................................................................................................................... 41 
7. References .................................................................................................................................... 42 
Acknowledgements ............................................................................................................................... 47 
Appendix 1 ............................................................................................................................................ 48 
Appendix 2 ............................................................................................................................................ 50 
Appendix 3 ............................................................................................................................................ 52 
Appendix 4 ............................................................................................................................................ 54 
Appendix 5 ............................................................................................................................................ 60 
 
  
6 
 
Abbreviations 
BC  buffy coat 
CAD  compound adsorption device 
DNA  deoxyribonucleic acid 
HBC  hepatitis B virus 
Hct  hematocrit 
HCV  hepatitis C virus 
HIV  human immunodeficiency virus 
HTLV  human T-lymphotropic virus 
NAT  nucleic acid testing 
NEMC North Estonia Medical Centre 
PC  platelet concentrate 
PI  pathogen inactivation 
PLT  platelet 
PRP  platelet-rich plasma 
RBC  red blood cell 
RCF  relative centrifugal force 
RNA  ribonucleic acid 
RPM  revolutions per minute 
SCD  sterile connecting device 
TTI  transfusion-transmissible infection 
vCJD  variant Creutzfeldt-Jakob disease 
WBC  white blood cell 
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1. Introduction 
Though saving lives, transfusion of donor blood also poses risk of various adverse reactions in 
patients. Since the beginning of transfusion therapy, a lot of effort has been put to enhance the 
safety of blood products through the development and implementation of screening and 
processing procedures. The newest concept in blood transfusion safety can be considered the 
pathogen inactivation technology – a promising advancement for managing the risk of both 
well-known and emergent transfusion transmissible infections, as well as bacterial 
contamination. 
Since the development of different pathogen inactivation systems, a great number of studies 
have been conducted to assess the toxicity, pathogen inactivation capability, impact on blood 
product, and the subsequent clinical outcome for patient. The findings of those studies can be 
considered more or less universally applicable, provided that the pathogen inactivation system 
has been implemented according to the requirements set by the producer. The proper 
validation and subsequent correct usage of the system is the responsibility of the blood 
establishment and ensures the maximum efficacy and safety the technology can provide. 
North Estonia Medical Centre´s Blood Centre is the biggest blood establishment in Estonia, 
collecting, processing, and providing over half of the country´s blood supply. The author of 
this thesis is working as a production specialist in the abovementioned organization and had 
an opportunity to test the pathogen inactivation of buffy coat platelet concentrates by Intercept 
platelet processing set from October 2014 to March 2015. Testing comprised of two 
validations and subsequent limited production of pathogen inactivated platelet products. The 
aim of the testing and this thesis was to develop a method for production of buffy coat platelet 
concentrates that would meet two sets of requirements: firstly the criteria for platelet products 
suitable for use with Intercept system and subsequently, after Intercept treatment, the required 
and recommended quality characteristics for pooled buffy coat platelets in additive solution. 
In chapter 2 the composition and functions of blood are briefly introduced, followed by the 
explanation of main principles for collecting donor blood and processing it into blood 
components. The main indications for platelet concentrate transfusion are mentioned, as well 
as the transfusion safety concerns brought out with an emphasis on risks regarding pathogen 
transmission. Also an overview of pathogen inactivation technologies on market is given and 
the methods for platelet concentrate pathogen inactivation explained. The experimental work 
is described in chapter 3 and the results are presented and discussed in chapter 4.  
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2. Literature overview 
2.1 Composition of blood 
Blood is a living tissue composed of liquid called plasma and cellular components: red blood 
cells (erythrocytes), white blood cells (leucocytes), and platelets (thrombocytes). Blood 
accounts approximately 6 – 8% of adult body weight. Normal adult blood volume for men is 
5.0 – 6.0 and for women 4.5 – 5.5 liters. The usual count of cells in one micro liter of blood is 
4.2 – 6.2 million for red blood cells (men have usually higher concentrations than women), 
7000 – 10 000 for white blood cells, and 150 000 – 350 000 for platelets [1]. 
Plasma forms about 55% of the total volume of blood and consists of water (about 91.5%) and 
dissolved organic and inorganic substances such as plasma proteins (albumins, globulins, 
fibrinogen), organic materials (sugars, amino acids, lipids), inorganic electrolytes, hormones, 
blood gases, and waste products (urea, creatinine, uric acid, bilirubin). Main functions of 
plasma include transport of substances, release of heat from the body core, maintenance of 
osmotic pressure, as well as contribution to the acid-base balance, blood coagulation, and 
immune responses [2]. 
More than 99% of blood cells are red blood cells. The hematocrit is defined as the percentage 
of blood volume that is occupied by red blood cells. The normal hematocrit in men is about 
45% and in women 42%. Red blood cells have a size of 7 µm in diameter and a shape of 
biconcave disk that produces large surface area and makes them very flexible, allowing to be 
squeezed in small capillaries without rupture. The main functions of red blood cells are to 
carry oxygen taken in by lungs and carbon dioxide produced by cells. Red blood cells contain 
large amount of the protein hemoglobin, with which oxygen and, to a lesser extent, carbon 
dioxide reversibly combine [3]. 
The site of red blood cell production and differentiation is bone marrow. During the 
maturation, red blood cells lose their nuclei and other organelles before entering the 
circulation. After that, they can neither reproduce themselves nor maintain their normal 
structure for very long. The average lifespan of a red blood cell is approximately 120 days. 
Red blood cell destruction normally occurs in the spleen or in the liver, and most of the iron 
released in the process is conserved [3]. 
White blood cells are a versatile group of blood cells (neutrophils, basophils, eosinophils, 
monocytes, B and T lymphocytes) that contribute to the immune response in case of foreign 
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invaders, such as microorganisms. White blood cells differ in size (smallest are lymphocytes, 
8 – 10 µm in diameter, and largest are monocytes, 15 – 20 µm in diameter) and cellular 
composition. They all have nucleus and some of them contain large cytoplasmic granules. All 
classes of white blood cells are produced in the bone marrow but some types undergo further 
development and cell division in lymphoid tissues outside bone marrow. White blood cells are 
part of a system of defensive cells that phagocytize material, detoxify poisons, produce 
antibodies, and release chemical messengers, enzymes, and other substances. Each type of 
white blood cells has a different function contributing to an integrated and effective body 
defense [1]. 
A platelet is a cell fragment split from a large cell called megakaryocyte. One megakaryocyte 
gives rise to about 6000 platelets. Megacaryocytes develop in bone marrow and most of them 
stay there releasing platelets into bloodstream. Some megacaryocytes enter blood and travel to 
other organs (particularly the lung) where they remain to produce platelets. Circulating 
platelets have a lifespan of approximately 1 – 2 weeks. If not consumed in the process of 
blood coagulation, platelets are destroyed by macrophages in the liver and spleen [1]. 
Platelets are small, about 2 – 4 µm in diameter, membrane-bounded bodies without nuclei. 
They play several important roles in hemostasis. Following injury,  platelets release chemicals 
to the lining of blood vessels, where they stimulate the contraction of the vessel wall in order 
to minimize blood loss. Because of their adhesive properties, platelets clump together forming 
a plug to the vessel wall. In addition, they participate in the formation of  factors that initiate 
coagulation of blood and they release growth factors that promote repair after vascular injury 
[1]. 
2.2 Blood collection and processing 
By the data collected from 179 countries for the period of 2011 – 2013 by World Health 
Organization, it was estimated that globally about 112.5 million blood donations are collected 
in a year [4].  A safe and sufficient supply of blood is an essential part of medical services. In 
many medical cases the transfusion of blood collected from voluntary donors can be the only 
life-saving treatment as, despite of an effort to develop artificial blood, no effective alternative 
to completely replace the donated blood have been found as of today [5, 6]. 
Blood products are considered to be medication and all the activities required to maintain the 
sufficient blood supply are the responsibility of blood establishments acting according to the 
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legislation and recommendations regulating collection, testing, processing, distribution, and 
quality issues of donated blood [5, 7]. In Estonia, the activity license for the blood 
establishment is given and the regular surveillance conducted by the State Agency of 
Medicines [7, 8]. From 2003 there are four blood establishments belonging to hospitals and 
working independently from each other: North-Estonia Medical Centre´s Blood Centre, Tartu 
University Hospital´s Blood Centre, Pärnu Hospital´s Blood Centre, and East-Viru Central 
Hospital´s Blood Centre. Slightly more than half of the donated blood is collected, processed 
and issued by NEMC Blood Centre [9]. 
2.2.1 Blood collection 
Blood is collected from voluntary donors. Before the donation, the medical condition of the 
donor is examined (for instance weight taken, hemoglobin and blood pressure measured) and 
questions asked about the medical history, travel, and lifestyle. All that is done to ensure the 
donation will be safe for the donor and the blood collected suitable for transfusion [5, 10]. 
The blood from donor can be taken by whole blood collection or apheresis procedure [11]. 
In whole blood collection, 450 ml ± 10% of blood is collected by phlebotomy into the primary 
bag of sterile blood collection system, where it is mixed with anticoagulant to prevent 
clotting. The volume of blood has to be in the abovementioned range, otherwise the blood 
cells may be damaged or anticoagulation may not be satisfactory. The actual time for 
phlebotomy and bleeding is usually less than 10 minutes, but the maximum of 15 minutes is 
mostly allowed, otherwise clots may form in the tubing before the blood mixes with the 
anticoagulant in container. The blood collection system is made of plasticized material that is 
biocompatible with blood cells and can be used only once [10]. After collection, the blood is 
cooled down to 20 – 24º C and kept at that temperature for up to 24 hours, until further 
processing [12]. The temperature around 22º C is required to maintain the activity of platelets. 
The cooling and maintenance of collected blood at room temperature is done by placing the 
units after collection into specific containers [10]. 
During apheresis procedure, blood is passed through specific device that separates out one 
particular constituent of whole blood and the remainder is returned to the donor. Usually the 
red blood cells are returned as that is the portion of blood that takes the longest to replace and 
apheresis procedure is used to collect either plasma, platelets, or both. Using this method an 
individual can donate plasma or platelets much more frequently than they can safely donate 
whole blood [5, 11]. 
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2.2.2 From whole blood to blood components 
Starting from collection, some coagulation factors, especially V and VIII, decrease rapidly in 
quantity and platelets start losing viability in stored whole blood. Therefore, to retain most of 
the functionality of whole blood constituents and to enable the optimum utilization of limited 
donor blood, the whole blood is separated into components – plasma, red blood cells, and 
platelets. As mostly the condition of the patient requires transfusion of just one or few 
components of blood, and in some situations transfusion of components in ratios not 
ordinarily found in whole blood is necessary, the whole blood in developed countries is rarely 
transfused. Despite of the general move to blood component therapy, a widespread transfusion 
of whole blood has continued in resource poor developing countries [10, 11]. 
Component production from whole blood consists of centrifugation to separate out plasma 
and cells of different density, followed by manual or automated transfer of components from 
the primary collection bag of the blood collection system to transfer packs. The blood 
collection system contains multiple bags connected by tubing so that the components can be 
transferred between bags in a closed system to maintain sterility [5, 10]. 
There are two general methods for whole blood processing – buffy coat (BC) method long 
favored in Europe and adopted recently in Canada and platelet-rich plasma (PRP) method still 
standard in USA. These methods differ by whole blood centrifugation program, first 
separation step, and further platelet processing [5, 10, 13]. 
For BC method, the centrifugation of whole blood uses relatively high centrifugal force and is 
therefore called hard spin centrifugation, resulting in formation of three distinctive layers – 
the denser red cells settle in the bottom, leaving plasma on top, while thin white layer called 
buffy coat, containing most of the platelets and white blood cells, forms in between. With the 
aid of blood separator, plasma is transferred into empty satellite bag connected to the top of 
primary bag. Red blood cells are transferred into the satellite bag connected to the bottom of 
primary bag, where they are mixed with appropriate storage solution, forming red blood cell 
suspension (see picture 1). The buffy coat layer, with a fraction of plasma and red blood cells, 
will stay in the primary bag, and those bags, called buffy coat bags, are further used for 
production of platelet concentrates [10]. 
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Picture 1. Whole blood separation by BC method. 
The initial step for platelet concentrate production by BC method is pooling together a 
number of buffy coats (usually 4 to 6) with platelet storage solution, followed by 
centrifugation of BC pool with lower centrifugal force (soft spin) program resulting in 
settlement of heavier cells (red blood cells and white blood cells), while leaving most of the 
platelets suspended in mixture of plasma and storage solution in the upper part of the BC pool 
bag. That mixture of plasma, storage solution, and platelets is then transferred either by 
manual or automated separation devices into the platelet concentrate storage container (see 
picture 2) [10, 12]. 
 
Picture 2. Preparation of platelet concentrate by BC method. 
In PRP processing method, a soft spin is used for the centrifugation of whole blood, resulting 
in settlement of red blood cells and white blood cells in the bottom, leaving most of the 
platelets suspended in plasma on top. Platelet-rich plasma is then separated into satellite bag 
and subsequent centrifugation with hard spin is used, resulting settlement of platelets on 
bottom, allowing separation of almost cell free plasma from top of the container into the next 
satellite bag. The platelets are then resuspended in about 50 ml of plasma left [10] and  4 – 6 
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such single unit platelet concentrates can be connected and pooled together to form a 
therapeutically effective dose [12]. 
2.2.3 Storage of blood components 
To preserve adequate amount of plasma proteins, plasma should be separated from whole 
blood and frozen within 24 hours of collection. Freezing must take place in a system that 
allows to bring the core temperature down to  -30º C within 60 minutes. After freezing, 
plasma must be stored at temperature -25º C or below. At that temperature, storage for up to 3 
years is allowed. Storing at temperatures from -18º C to -25º C is also allowed, but in this case 
plasma should be used within 3 months [12]. 
Red blood cells are stored at controlled temperature between 2º C and 6º C [12]. The storage 
time depends on anti-coagulant/preservative system but the common red blood cell 
suspension storage period is either 35 or 42 days counting from the day of collection [11, 12]. 
Platelet concentrates are stored with constant agitation at 22 ± 2º C in oxygen permeable 
plastic containers. Platelets should never be placed into refrigerator as this impairs the 
recovery and survival of platelets following transfusion [5]. The storage time of 5 days can be 
extended to 7 days if suitable additive solution and detection of bacterial contamination or 
pathogen inactivation is used [12]. During storage, platelets undergo a fall in pH due to 
accumulation of lactate and change from discoid to round. Clinical significance of changes in 
shape and function during platelet storage are debatable and difficult to routinely monitor [5, 
14, 15]. Therefore pH remains the only adequate change that should be monitored routinely 
and must be above 6.4 at outdate [12]. 
2.3 Clinical use of platelet concentrates 
Platelet transfusion therapy has made major contributions to the care of patients with a variety 
of medical conditions. Most platelet transfusions are used for the prevention of bleeding 
rather than for treatment of active bleeding [10, 16, 17]. The cause of thrombocytopenia 
should be established before the decision about the use of platelet concentrate is made as 
transfusion may not be necessarily indicated. The causes for thrombocytopenia that might 
require platelet transfusion are chemotherapy for hematologic cancers and solid tumors, 
hematopoietic stem-cell transplantation, massive blood loss during trauma or surgery, and 
inherited or acquired qualitative defects in platelets. The decision whether to transfuse 
platelets should depend on the clinical condition of the patient, the cause of 
14 
 
thrombocytopenia, the platelet count, and the functional ability of patient’s own platelets [10, 
12, 18, 19]. 
The widely used term “transfusion trigger” refers to the hematologic value at which a 
transfusion is given. For platelet transfusions the patient platelet count as transfusion trigger 
has been frequently used. Prophylactic transfusions are often given when the patient platelet 
count is less than 5 – 10 x 109 in liter. In presence of fever, local injuries or coagulation 
disorders the prophylactic transfusion in case of platelet count above 15 – 20 x 109 in liter 
may be required [10, 12]. 
Over the years, growing concerns about unnecessary overtransfusions have risen and a 
number of studies have been conducted to determine the optimal trigger, optimal dose, and 
the effectiveness of therapeutic only transfusion strategy for different medical conditions. 
Some of these trials have indicated that a smaller dose, lower transfusion triggers and a 
therapeutic rather than preventive strategy could be used with the same clinical outcome [10, 
18, 20 - 23]. 
The number of platelet concentrates transfused in Estonia for the period 2010 - 2015 
(separately for BC, apheresis, and all platelet concentrates together) are given in table 1. 
Table 1. Transfused platelet concentrate doses in Estonia [24]. 
Year 2010 2011 2012 2013 2014 2015 
BC PC 4134 4902 5712 5795 5279 5622 
Apheresis PC 1282 1357 1273 1465 1451 1609 
All PC 5416 6259 6985 7260 6730 7231 
 
2.4 Blood transfusion safety 
Though saving lives, blood transfusion also poses a variety of risks to the recipient´s health. 
Transfusion reactions are unintended responses in a patient that are associated with the 
transfusion of blood or blood products. Transfusion complications can be broadly categorized 
as immunologic and non-immunologic. Immunologic complications are due to introducing a 
non-self biologic matter to recipient´s immune system. It´s also possible that white blood cells 
or antibodies present in donor blood start acting against patient´s cells. Non-immunologic 
complications are the transmission of a pathogen or can be physiological effects in patient not 
related to immune system (cardiac overload, citrate toxicity, iron overload, hypothermia). 
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Adverse reactions from transfusion can be acute (occurring within 6 hours of transfusion) or 
may emerge days, months or years later [10, 11]. 
A well legislated and regulated blood transfusion service is a cornerstone for assuring safety 
of the blood supply within a country. The European Directive 2002/98/EC sets standards 
relating to blood collection, testing, processing, and storage [25]. These requirements from the 
EU Directive have been transposed into Blood Act that, together with specifying regulations 
(based on Blood Act and Communicable Diseases Prevention and Control Act) established by 
the minister responsible for the area, create the legislation regulating all aspects of blood 
service in Estonia [7, 26, 27]. In addition to legislation, blood establishments often follow 
non-binding recommendations such as “Guide to the preparation, use and quality assurance of 
blood components” to standardize the blood service practice [12]. 
The blood establishment must have an effective quality management system to control the 
whole operation. In addition, the hemovigilance system in a country must be set up to ensure 
the traceability from donor to the recipient and vice versa. Hemovigilance is a set of 
surveillance procedures covering the entire vein-to-vein transfusion chain (from the donation 
of blood or its components to the follow-up of recipients of transfusion) intended for 
collecting and assessing information on unexpected or undesirable effects from the use of 
blood products. Hemovigilance system allows recognition of risks and improvement of the 
transfusion system [5, 12, 27]. 
2.4.1 Transfusion-transmissible infections 
A number of pathogens, including viruses, bacteria, protozoan parasites, and one prion are 
known to be transmitted by transfusion. Measures are in place to control such transmission, 
including blood donor selection, laboratory testing and component processing [5]. 
Protozoan infections are endemic mainly in tropical countries. Most notable transfusion-
transmissible protozoan infections are malaria (caused by different species in genus 
Plasmodium transmitted by mosquitoes), babesiosis (caused by variety of species in genus 
Babesia transmitted by ticks) and Chagas disease (caused by Trypanosoma cruzi transmitted 
by reduviid bugs). In non-endemic areas like Europe, malaria, Chagas disease, and babesiosis 
are imported diseases for which prevention depends mainly on deferral of donors for few 
month after travel to endemic area [5, 11, 28]. 
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It is now clear that at least one prion that causes the variant Creutzfeldt-Jakob disease (vCJD) 
can be transmitted by transfusion [29]. vCJD is the human form of bovine spongiform 
encephalopathy (mad cow disease), that can be transmitted to humans through ingestion of 
tissues from infected cattle. The detection of prion caused disease transmission is difficult, as 
the incubation period, before the symptoms emerge, is several years. The disease is a concern 
mainly in the United Kingdom, where domestic plasma was partly eliminated for transfusion 
and fractionation. Also the universal white blood cell reduction of blood components was 
implemented, as it was believed to reduce the risk of transmission [5]. Tests suitable for 
screening donors for vCJD infection and filters for prion protein removal are under 
development [30 - 32]. In NEMC Blood Centre the donors who have been living in the United 
Kingdom or Ireland between 1980 – 1996 for more than 6 month or who have had blood 
transfusion there since 1980 are permanently deferred [33]. 
Common bacterial infection known to be transfusion-transmissible is syphilis (caused by 
Treponema pallidum) and it was the first infection routinely tested in blood donors since 
1950-s [10]. It´s questionable whether the Lyme disease (caused by bacteria in genus 
Borrelia) or other bacteria and viruses known to be transmitted to humans by ticks can be 
transmitted by blood products [34 - 37] but, for precautionary reasons, in Estonia donors are 
deferred for two month after tick bite [28]. 
The most numerous transfusion-transmissible infections are viruses, including human 
immunodeficiency virus (HIV), hepatitis A, B, C and E viruses (HAV, HBV, HCV, HEV), 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), human T-lympotrophic virus (HTLV), 
parvovirus B19, etc. [5, 11]. Risk of transmission has become extremely low for HIV, HCV, 
and HBC infections due to testing of every donation. Residual risk is mostly attributable to 
window period – a period after infection when donor is already infectious but has a negative 
test result [5, 10]. Due to implementation of assays based on nucleic acid testing (NAT) 
technology, the window period has diminished to only few days for HIV and HCV and to two 
weeks for HBV if testing is done from single donations (not from pools of several donations) 
[38]. The residual risk for transmission of HIV, HCV, and HBV are usually less than one case 
per million components transfused [39 - 41]. 
In Estonia every blood donation is tested with immunoassays for antibodies against HIV, 
antibodies against HCV, HBV surface antigen, and antibodies against Treponema palladium. 
NAT testing is used to screen donor blood for HIV RNA, HCV RNA and HBV DNA [42]. 
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Those are the most common infection markers screened in donor blood. Some countries 
additionally test donor blood for other infectious diseases like HTLV (USA, Canada, UK, 
France, and Australia), malaria for selected donors (France, UK, and Australia), Chagas 
disease for selected donors (USA, Canada, France, UK), etc. [5]. 
In addition to well-known transfusion-transmissible diseases, the emerging infections 
represent a serious challenge for blood transfusion safety: West Nile virus (USA), 
Chikungunya virus (Indian Ocean),  Zika virus (Latin America),  Dengue (Asia, Africa, Latin 
America), etc. [5, 11, 43 - 45]. The strategy to prevent the transmission of the emerging 
disease depends on the prevalence of the infection in the donor population, existence of the 
effective treatment for the disease, availability of a suitable screening assay, and recently also 
the possibility for inactivation of the pathogen through blood product treatment [5]. 
A possible, but rather unsatisfactory approach would be to focus on the recipient, by 
diagnosing and treating the infection in case of transmission. This, of course, works only for 
treatable infections. An example of this approach has been a management of transfusion 
transmitted babesiosis in USA, though screening assays are now in development to test blood 
donors in endemic areas [5, 46 - 49]. 
If the disease is not endemic in the area and is localized in certain regions, so that a possible 
infection risk can be assessed based on a travel of the donor, the deferral of possible infectious 
donors based on questionnaire can be a relatively inexpensive method to ensure blood supply 
safety. Nevertheless, donor´s failure to answer the questions correctly may lead to the 
collection of an infectious blood unit. It is also not generally possible to define the endemic 
area so that all those who are infected would be effectively deferred without an unreasonable 
loss of donors. Therefore, when formulating the restrictions for donors, the possible negative 
impact on blood availability also has to be considered [5]. 
Implementation of a screening test is a complex issue. It´s important to consider the 
prevalence of the disease in donor population, likelihood of the transmission, sensitivity and 
specificity of the test. Tests that perform well in patient population may result a considerable 
number of false-positive results in donor population. Strategy to deal with positive test results 
must be in place – confirmatory testing should be possible and procedures to communicate 
both the true and false positive test results to donors must be worked out [10].  
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In the past only serologic tests were available but now NAT testing is also a possibility. As 
usually considered more sensitive and specific, NAT testing may be a better solution in most 
cases but not always, as some diseases (particularly parasitic ones) result in a long-term 
infection with very low levels of infectious agent in the bloodstream. In those cases, a better 
option would be to test antibodies against the infectious agent in the donor blood as antibodies 
remain usually in detectable level [5]. 
A new approach to manage the risk of TTI-s is the pathogen inactivation technology 
(described in chapter 2.5), implemented in number of countries for today. An example of the 
use of novel technology to manage the epidemics of emerging virus was the implementation 
of pathogen inactivation for platelets in the island La Reunion during a large outbreak of 
chikungunya virus infection [5, 50]. 
2.4.2 Bacterial contamination 
Collected blood may become contaminated with bacteria due to donor bacteremia or by 
introducing the bacteria from donor skin at the time of collection. The contamination from the 
environment during processing is rare but can occasionally happen. Bacterial contamination 
used to be a huge problem for the early blood transfusions but due to implementation of single 
use sterile needle and blood container, the incidence of contamination has decreased 
immensely but has not been eliminated completely. Other safety measures to avoid bacterial 
contamination are deferral of donors based on gastrointestinal disease or recent dental work, 
effective skin disinfection at phlebotomy site, diversion of the first 20 – 40 ml of collected 
blood, and maintaining a closed system during blood processing using devices that allow 
sterile connections and interruptions between blood containers [5, 10]. 
To further reduce the transfusion of blood contaminated with bacteria, it´s possible to test 
blood products for bacterial growth. Mostly platelet concentrates are tested due to their higher 
risk for rapid bacterial growth. But despite of the bacterial culture systems used, it´s been 
estimated that quite a lot of contamination is still unrecognized. One of the reasons being the 
low concentration of bacteria at the time of sampling but subsequent rapid growth during 
platelet concentrate storage. With the approach to let the possible bacteria contaminating the 
platelet concentrate to incubate a bit before sampling, the product cannot be issued for a day 
or two, which is a long time considering the short storage period for platelets. Another 
approach is to sample platelet concentrates on the day of production and incubate the sample 
for seven days in bacterial detection system. The product can be issued any time during 
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storage period as long as the bacterial growth has not been detected at the time of release [5, 
10, 12, 51]. Due to possible false negative results, it´s been suggested that pathogen 
inactivation would be a better alternative for bacterial screening to manage the bacterial 
contamination in platelet concentrates [52]. 
The magnitude of the clinical problem of contaminated blood products is difficult to define, as 
mostly only more severe reactions are reported [53]. The severity of reaction usually depends 
on the patient´s underlying condition, the amount and type of bacteria, and presence of 
endotoxin in the blood component [10]. The predominant blood component bacterial 
contaminants are aerobic and anaerobic Gram-positive bacteria that belong to the normal skin 
flora and, more rarely, Gram-negative bacteria that originate from silent donor bacteremia or 
is part of the transient skin flora [5, 51].  It´s not possible to completely decontaminate skin 
and it´s been reported that normal skin bacteria like Staphylococcus epidermidis can survive 
the skin disinfection [54]. Low level bacteremia may occur in the incubation or recovery 
phase of acute infections after procedures such as tooth extraction [5]. 
Platelet concentrates are the main concern related to bacterial contamination, as the storage 
conditions (agitation in a storage solution at room temperature) are suitable for the growth of 
variety of bacteria. Gram-positive aerobic or facultative anaerobic bacteria are the 
predominant platelet concentrate contaminants, though strict anaerobic organisms have been 
found. Although able to survive and proliferate in platelet concentrates, most of them are not 
considered to be pathogenic [5, 10]. 
Propionibacteria and Staphylococci  are the most dominant PC contaminants. Staphylococcus 
epidermidis is a commonly isolated bacteria and transfusions can have a fatal outcome [5, 53, 
55]. Missed detection is attributed to low initial concentration and the ability of some strains 
of Staphylococcus epidermidis to form slimy bacterial aggregates that can attach to platelet 
concentrate storage container [56]. Anaerobe Proprionibacterium acnes is another common 
platelet contaminant but the clinical significance of this bacteria is still debatable [57]. Other 
bacteria often associated with PC include Staphylococcus aureus, corynebacteria, 
Streptococcus, Bacillus, etc. Although less common, Gram negative bacteria have been found 
in PC and can cause a severe infection due to endotoxins [5, 53]. 
Red blood cell suspensions are stored at refrigerator temperature where most of the bacteria 
will not proliferate [10, 11]. The contamination of red blood cell suspensions with cold-
growing organisms is rare and usually involves Y. enterocolitica due to its ability to grow at 
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refrigerator temperatures. There is a rather long lag phase and most observations of 
contamination have been with units stored for 20 days or longer. Though the organism loses 
some of its virulence during growth, the endotoxins produced can have a severe clinical 
effect. As Y. enterocolitica infection in normal, healthy individuals is often asymptomatic or 
may be associated with mild gastrointestinal symptoms, questioning donors about 
gastrointestinal disease is not very effective for deferring donors who might have circulating 
organisms. Other red blood cell suspension contaminants are Serratia spp. Pseudomonas spp, 
Enterbacteria spp, Campylobacteria spp,  and Escherichia coli, all of which have the 
potential to cause endotoxic shock in recipients [5, 10, 58]. 
In Estonia, all platelet concentrates must be microbiologically tested using microbial 
incubation device and culture media suitable for growth of aerobic and anaerobic bacteria, 
unless the products are processed with pathogen inactivation system [59]. In NEMC Blood 
Centre BacT/ALERT is used to culture sample of every produced platelet concentrate (both 
BC and apheresis) in aerobic and anaerobic culture media bottles suitable for platelet 
concentrate testing. The sample is usually cultured on the day of production and is incubated 
for seven days. Platelet concentrates can be issued to hospitals on “negative-to-date” basis. If 
positive result is obtained after issuing, the hospital is informed. The microbial growth in the 
culture bottle has to be confirmed and bacteria identified. If platelet concentrate has been 
transfused, the sensitivity to antibiotics is also determined and results are communicated to 
the hospital. If the platelet concentrate giving the positive result has not been issued, it will be 
retested. Also the red blood cell suspensions connected to the positive result (through initial 
donations) are sampled and cultured [60]. 
In the period of 2010 – 2016, altogether 27 440 platelet concentrates have been tested in 
NEMC Blood Centre by BacT/ALERT. 154 of them gave positive result (0.6%) and for 62 
cases the microbial growth was confirmed (0.2%). The transfusion of 25 contaminated 
platelet concentrates was prevented but for 37 cases the positive result was obtained after 
transfusion. The most prevalent identified contaminant was Propionibacterium acnes (32 
cases), followed by Staphylococcus epidermidis (8 cases) and Staphylococcus hominis (4 
cases). Other identified bacteria included different Staphylococcus strains (saccharolyticus, 
aureus, haemolyticus, capitis, etc.), but also Peptostreptococcus prevotii, Dermacoccus 
nishinomiyaensis, Peptoniphilus asaccharolyticus, Micrococcus luteus, Porphyromonas 
gingivalis, Leuconostoc mesenteroides, Sphingomonas paucimobilis, Corynebacterium 
jeikeium, etc. [60]. 
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2.5 Pathogen inactivation technology 
The concept of pathogen inactivation (PI) technology is to damage pathogen nucleic acids 
using chemicals and/or treatment with visible or UV light. That would halter the replication 
and infectivity capability of broad range of viruses, bacteria and protozoa without affecting 
platelets and red blood cells that do not contain nucleus. Unfortunately, PI technology also has 
no effect on infectious prion proteins [5]. 
In literature, pathogen inactivation technologies have been also referred to as pathogen 
reduction technologies. As this terminology can be confusing, it has been suggested to use 
rather the term “inactivation” for methods that impair the replication and infectivity of 
pathogens but do not remove them from product (as using the term reduction would suggest) 
[61]. 
Pathogen inactivation technologies for plasma have been in use for more than 20 years. First 
methods were implemented by plasma fractionation companies for large pools of plasma to 
ensure the safety of produced plasma products. Later on, methods to pathogen inactivate 
single units of plasma came into market and were suitable for use in blood centers. 
Subsequent developments have been the adaption of those methods for usage on cellular 
blood components [5, 62]. 
Currently on market there are two methods for pathogen inactivation of plasma only: solvent-
detergent method (used at industrial scale) and Theraflex MB. Solvent-detergent method 
(Octaplas, Octapharma) is used at industrial scale to pathogen inactivate large pools of 
plasma. Method is based on treatment of plasma with organic solvent in combination with 
virucidal detergent. These chemicals are extracted later by oil and removed by 
chromotographic adsorption respectively. Theraflex MB system (MacoPharma) uses methylen 
blue and is implemented in many European countries for pathogen inactivation of plasma. 
Method can be applied to a single unit of plasma. Methylen Blue has a natural affinity for 
nucleic acids and when exposed to visible light (red/white), a photodynamic reaction 
generates reactive oxygen species, which specifically target the guanine residues of nucleic 
acids. Residual methylen blue is removed before freezing process [62]. 
Two methods can be applied for both plasma and platelets: Intercept and Mirasol. These 
systems are widely used in Europe and Intercept is also approved in the United States. One 
more system for platelets (Teraflex) is currently on phase III clinical trials stage. Also the 
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development of one method for red blood cells is under phase III clinical trials (Intercept 
system for red blood cells that uses amustaline and no UV light activation is required) and 
Mirasol system is being tested for the adoption to whole blood [62]. 
2.5.1 Intercept system for platelets 
Intercept pathogen inactivation system uses a synthetic photochemical compound amotosalen 
hydrochloric acid. During illumination with UVA light (320 – 400 nm) this compound reacts 
with pyrimidine bases of DNA or RNA and forms covalent bond that results in intra- or inter-
nucleic acid crosslinks. This kind of crosslinking halts replication of a pathogen. Amotosalen 
can quickly pass cellular membranes, bacterial walls or viral envelopes and interacts with 
nucleic acids without interacting with proteins or cellular lipids [62, 63]. 
 
Picture X. Pathogen inactivation mechanism of Intercept system [64]. 
For treatment with Intercept, platelets have to be suspended with plasma and platelet additive 
solution. Amotosalen is added and the mixture is exposed to UVA light for 4 – 6 minutes on 
continuous agitation in Intercept Illuminator [62, 63]. For the removal of most of the 
remaining amotosalen and the photo by-products of this reaction, the illuminated platelet 
concentrate has to stay in the container with compound adsorption device (CAD) for 6 – 16 
hours at room temperature with agitation. The CAD consists of spherical beads enclosed in a 
polyester mesh pouch within a plastic container [65]. After CAD phase platelets are 
transferred and stored in platelet storage bags. All these transfer steps can lead to up to 15% of 
platelet loss [62, 66]. 
Platelet concentrates that are to be treated with Intercept double-dose system must meet 
certain requirements. The plasma content 32 – 47% is required to ensure appropriate UVA 
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light transmission for maximum inactivation efficacy and minimal impact on platelet viability. 
Also red blood cells impede UVA light transmission, so the RBC concentration must be lower 
than 4 x 10
6
 in ml. As amotosalen volume in the system is fixed, the volume of platelet 
concentrate must be between 300 – 420 ml, so that the amotosalen concentration in the 
illumination container would be 120 – 180 µM. The platelet content before pathogen 
inactivation must be in range of 250 – 800 x 109 as that content of platelets has been validated 
by the producer during the system development [64]. 
 
Picture X. Intercept system for platelets with dual storage container [64]. 
2.5.2 Mirasol system for platelets 
Mirasol pathogen inactivation system uses riboflavin (vitamin B2), which is a naturally 
occurring photochemical compound. It binds to nucleic acid (DNA or RNA) bases and upon 
UV light illumination (at 265 – 370 nm), it oxidizes guanine bases resulting in single strand 
breaks in nucleic acids. This reaction is a result of direct electron transfer during the oxidation 
of the guanine bases, which later creates oxygen, peroxide and hydroxyl radicals that breaks 
DNA and RNA. These breaks are irreversible and cannot be repaired by any endogenous 
repair mechanism of pathogens. Riboflavin and its byproducts do not need to be removed 
after UV illumination as they are anyway present in natural foods and also in blood [62]. 
The treatment consists of adding riboflavin to the illumination bag containing the platelet 
concentrate unit. The platelet unit containing riboflavin is then subjected to UV illumination 
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in a controlled temperature and agitation for 10 minutes. About 3% of platelets are lost from 
bag to bag transfer [62, 67]. 
2.5.3 Theraflex system for platelets 
The Theraflex pathogen inactivation system for platelets does not involve adding a 
photochemical compound. It uses short wavelength monochromatic UVC light (254 nm) that 
has a unique ability to interfere with DNA and RNA replication while preserving protein 
integrity. Short wavelength UVC light leads to the formation of intra-strand or inter-strand 
cyclobutanepyrimidine and pyrimidine-pyrimidone dimers on DNA and RNA, subsequently 
halting replication. The Theraflex UVC treatment of PC consists of an illumination device 
(Macotronic UV illuminator) and processing kit (that contains an illumination bag, a storage 
bag, and a sampling bag). The platelet concentrate in illumination bag is placed into the UV 
illuminator under continuous high-speed agitation and exposed to UVC light for one minute. 
Platelets are then transferred to the storage bag. The whole treatment takes approximately 8 
minutes [62, 68]. 
2.5.4 Concerns regarding pathogen inactivation technology 
While the concept of inactivating pathogens in blood components is a promising method to 
achieve a whole new level in blood transfusion safety, the new treatment of blood also gives 
rise to multiple concerns. In addition to cost-effectiveness, three major criteria for the 
pathogen inactivation technology have been defined: it must target a broad spectrum of 
pathogens, it must not cause damage to the product, and it must be safe for the recipient [62, 
69]. 
To evaluate the efficacy of PI technology, multiple in vitro studies with products spiked with 
pathogen have been conducted. On those studies different pathogen inactivation systems show 
different inactivation capability for different pathogens. The problem arises from the fact that 
it has not been defined how much inactivation is enough, as it is not well known what is the 
minimal concentration of different pathogens that can cause the infection. Most probably the 
final evaluation of the efficacy of pathogen inactivation systems is possible only after certain 
period of routine use, comparing the hemogivilance data before and after the implementation 
[62, 63, 68 - 70]. 
For the approval of the pathogen inactivation system, thorough toxicity studies in animal 
models and clinical trials are required. The chemicals used and created during pathogen 
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inactivation process may pose a risk to the recipient´s health. In addition, those agents can 
modify the composition of blood components in a way that could trigger the immune 
response. As PI chemicals are, by design, capable of interacting and permanently modifying 
nucleic acids, they have a potential of being genotoxic, carcinogenic, and  harmful for the 
reproductive system. The potential toxicity of PI chemicals to patients needs to be studied for 
both acute and chronic administrations. No higher frequency of adverse reactions have been 
shown for PI technologies currently on market [63, 65, 68, 69] but the PI system developed 
for red blood cells (by Cerus corporation) had a drawback in III phase clinical trials when 
some of the patients formed antibodies against neoantigens formed on red blood cells during 
the PI process and the chemical amustaline (S-303) used in the PI system had to be changed in 
order to prevent such reactions in patients [71, 72]. 
The chemicals used in PI technology may interact with the cellular and plasma components of 
the transfusion product. It has been shown in in vitro studies that pathogen inactivation 
process can change the composition and function of the transfusion product. The significance 
of this effect can be to some extent evaluated by the in vitro characteristics and by predicting 
the in vivo importance of these changes. But the studies focusing on in vivo effects of PI 
products and on the final clinical outcome have shown that in vitro tests may not always 
correlate very well with in vivo performance as the clinical outcome in some of these studies 
has not been worse for PI blood components compared to control group. On the other hand, 
concerns are still existing that PI technology may result in increased demand for blood 
components due to losses in functionality and more studies are required to assess the effect of 
PI technologies on blood products [62, 67 - 69]. 
The whole capacity of PI technology to ensure blood safety cannot be used until systems 
suitable for red blood cells or whole blood are available for use, as only after implementing PI 
technology for all blood components, is it possible to get out the maximum of the benefits for 
the blood transfusion safety that PI technology can offer. Future will show if possibility to 
pathogen inactivate all blood products will remain as a complementary safety measure or will 
it also replace at least some of the screening and processing required today to ensure blood 
transfusion safety [5]. 
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3. Experimental 
3.1 Production- and measuring devices 
The following devices were used in production of platelet concentrates and Intercept pathogen 
inactivation process: 
 Heraeus Cryofuge 6000i centrifuges with rotor length 29.7 cm (Thermo Electron)  for 
centrifugation of whole blood and pooled buffy coat. 
 MacoPress Smart automatic blood components separators (MacoPharma) for the 
separation of centrifuged whole blood into plasma, red blood cell suspension, and 
buffy coat. 
 Hematron III heat sealers (Fenwal) for sterile sealing of tubing. 
 TSCD II sterile connecting devices (Terumo) for sterile welding of tubing. 
 Manual expressers (Fenwal) for separation of platelet concentrate from centrifuged 
pooled buffy coat. 
 CompoLift stand (Fresenius Kabi) for hanging blood bags during production 
processes. 
 Intercept Illuminator INT-100-50 (Cerus Corporation) for illuminating platelets with 
UVA light as part of Intercept pathogen inactivation process. 
 Helmer PC1200 platelet incubator and PFS84 platelet agitator (Helmer Labs) for 
agitating platelet concentrates during the CAD phase of Intercept pathogen 
inactivation process and for storage of platelet concentrates until expiry. 
The following measuring devices were used: 
 Sartorius BP8 scales (Sartorius AG) for measuring the weight of tare and of product at 
different steps of production. 
 Ruler for measuring the length of tubing at different steps of production. 
 Sysmex KX-21N automated hematology analyzer (Sysmex Corporation) for 
measuring hematocrit, platelet concentration and white blood cell concentration. 
 Inolab pH 730 pH meter with SenTix 81 electrode (WTW) for measuring pH of 
platelet concentrates 
 Intercept Platelets Colour Chart (Cerus Coropration) for assessing the RBC 
concentration in platelet concentrates. 
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3.2 Materials and aids in production process 
The following materials and aids were used in production: 
 Triple blood bag system comprised of 600 ml bag with 63 ml of CPD solution, 500 ml 
bag with 100 ml of SAGM solution, and 500 ml empty bag (MacoPharma; REF: 
1MAMRT6281LU or 1MAMRT6280LU) for collection, centrifugation, and separation 
of whole blood. 
 SSP+ 300 ml storage solution for platelets (MacoPharma; REF: SMASSP2030U) for 
production of 6BC platelet concentrates. 
 Storage container for platelet concentrates (Fenwal; REF: 1FE00R7041) for 
production of 6BC platelet concentrates. 
 Intercept platelet processing set with dual storage containers (Cerus; REF: 
OCEINT2503) for pathogen inactivation of 6BC platelet concentrates; 
 Different pouch bags for sampling. 
 Clamps. 
 
3.3 Weight of tare 
For the purpose of calculating the volume of the product at different steps of platelet 
concentrate production and Intercept pathogen inactivation process, all blood bags that were 
used in the process were weighed with specified tubing length. The tare weights with 
description and pictures are presented in appendix 1, table 4. 
3.4 Buffy coat production 
Approximately 450 ml of whole blood collected into 600 ml blood bag with 63 ml of CPD 
solution (part of triple blood bag system) was centrifuged by the following program: 
 RPM 3500 
 RCF 4068 
 Acceleration 7 
 Deceleration 5 
 Time 15 min 
 Temperature 22 C 
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Centrifuged whole blood was separated with automatic blood separators into plasma (500 ml 
empty blood bag), red blood cell suspension (500 ml blood bag with 100 ml of SAGM 
solution), and buffy coat (remained in the 600 ml blood bag that was used for collecting 
whole blood). The separation was done by the program validated in 2013. 
3.5 Validation of 6BC platelet concentrate production 
To assess, whether using 6 buffy coats and 300 ml of SSP+ solution we obtain platelet 
concentrates that meet the requirements set for Intercept pathogen inactivation process, 12 
6BC platelet concentrates were made as described below. 
6 BC bags and a bag of SSP+ solution were connected using SCD in a row, keeping between 
the buffy coat bags the length of  plasma tube 15 cm and the length of RBC tube as short as 
possible, and between the BC bag and SSP+ solution bag the plasma tube of BC bag 20 cm. 
The chain of buffy coats and storage solution was hanged onto the stand and blood in all buffy 
coat bags were let to flow into the lowest buffy coat bag. The buffy coat bags were rinsed by 
letting the storage solution flow from top into the lowest buffy coat bag (rinsing was done 
twice, using both times about half of the storage solution volume). The pooled buffy coat bag 
was sealed off from the chain (leaving the hose length 20 cm), weighed and sampled. The 
pooled buffy coat bag was connected to the storage container of platelet concentrate using 
SCD and centrifuged by the following centrifugation program: 
RPM 1180 
 RCF 462 
 Acceleration 5 
 Deceleration 3 
 Time 9 min 
 Temperature 22 C 
The platelet concentrate was separated into the storage container from the centrifuged pooled 
buffy coat by manual expresser and the pooled BC bag was sealed off. The platelet 
concentrate in storage container (with hose length 10 cm) was weighed and sampled. 
The color of platelet concentrate was assessed by visual inspection (for the estimation of RBC 
concentration) with the aid of Intercept platelets color chart. Sample of pooled buffy coat and 
6BC platelet concentrate were analyzed by hematology analyzer in quality control laboratory 
of NEMC Blood Centre. 
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3.6 Validation of 6BC platelet concentrate pathogen inactivation by 
Intercept platelet processing set with dual storage containers 
Validation of pathogen inactivation of 6BC platelet concentrate comprised of producing 12 
6BC platelet concentrates, following the treatment with Intercept platelet processing set with 
dual storage containers. The purpose of the validation was to see the parameters of the final 
platelet concentrate product. 
The 6BC platelet concentrates were made in the same way and the same data was collected as 
during the validation of 6BC platelet concentrate production (see chapter 3.5). Additionally, 
also the weight of 6BC PC after sampling was taken. 
The platelet concentrate storage container was connected to the amotosalen container of 
Intercept pathogen inactivation system by using SCD and hanged on the stand. Both the lower 
and the higher cannula of amotosalen container were broken and the 6BC platelet concentrate 
was let to flow with 17.5  ml of amotosalen solution into the illumination bag. Platelets in 
illumination bag were thoroughly mixed by gentle agitation and the air from illumination bag 
was expressed to amotosalen container. Small amount of platelet and amotosalen mixture was 
expressed to the tubing connecting illumination bag with amotosalen container and the 
amotosalen container with empty platelet concentrate storage container was sealed off so that 
the tubing was no longer than approximately 4 cm from the illumination container inlet port. 
The discarded amotosalen container with platelet concentrate storage container was weighed. 
Platelet concentrate in illumination container was illuminated with UVA light for 4 – 6 
minutes by using the Intercept Illuminator. Illuminated platelets with Intercept system were 
hanged on the stand, the cannula was broken and the platelet concentrate was let to flow into 
CAD container. Using manual expresser, the air was expressed from CAD container to 
illumination container and the tubing between CAD and illumination container was sealed 
close to the inlet port of CAD container. Empty illumination bag was removed and weighed. 
CAD container with platelets was placed on the flat agitator until early next morning, making 
sure the CAD agitation duration was between 6 to 16 hours. 
After CAD agitation, the platelet concentrate in CAD container was hanged on the stand, air 
from platelet sampling pouches (one on both storage containers) was expressed, and the 
sampling pouches were closed with clamps. Cannula was broken and platelets were allowed 
to flow into both of the two storage containers. Air was expressed from both storage 
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containers into CAD container, the tubing was clamped and sealed above the Y-fitting, and the 
empty CAD container was removed and weighed. The platelet concentrate in two connected 
storage containers was weighed, sample of platelet concentrate was taken into one of the two 
pouches, and both pouches were sealed off. The platelet concentrate was equally divided 
between the two storage containers and both containers were sealed off from the Y-fitting 
(leaving the storage container tubing 10 cm) and weighed. 
Sample of pooled buffy coat, platelet concentrate before and after the Intercept treatment were 
analyzed by hematology analyzer and pH of the Intercept treated platelet concentrate was 
measured in quality control laboratory of NEMC Blood Centre. From platelet concentrates 
obtained from 5 Intercept pathogen inactivation processes (all together 10 PC products) the 
sample was taken on expiry (7
th
 day of storage) to be analyzed by hematology analyzer and 
pH meter. 
3.7 Production after validations 
After validation, 47 6BC platelet concentrates were processed with Intercept pathogen 
inactivation system (from January to March 2015), producing all together 94 pathogen 
inactivated platelet concentrates. For 26 Intercept processes, the weight of the 6BC PC after 
sampling and Intercept treated platelet concentrates after sampling and splitting were taken 
and the samples of PC before and after the Intercept treatment were analyzed by hematology 
analyzer. 
3.8 Collected data and calculations 
3.8.1 Collected data 
The following data was collected during validation of 6BC PC production: 
 For BC pool: weight including tare before sampling, PLT concentration, hematocrit. 
 For 6BC PC: weight including tare before sampling, PLT concentration, RBC 
concentration (visual assessment of acceptability). 
The following data was collected during validation of 6BC PC pathogen inactivation with 
Intercept platelet processing set with dual storage containers: 
 For BC pool: weight including tare before sampling, PLT concentration, hematocrit. 
 For 6BC PC: weight including tare before and after sampling, PLT concentration, 
RBC concentration (visual assessment of acceptability). 
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 During the Intercept treatment, the weights of the following discarded containers were 
taken: PC storage container connected to amotosalen container, illumination bag, CAD 
container. Also the weight of Intercept treated PC before sampling and split was taken. 
 For Intercept treated PC: weight including tare after sampling and split, PLT 
concentration, WBC concentration, pH. 
 For 10 Intercept treated PC (from 5 Intercept treatment processes) on 7th storage day: 
PLT concentration and pH. 
After validation, the following data was collected for 26 Intercept treatment processes: 
 For 6BC PC: weight including tare after sampling, PLT concentration. 
 For Intercept treated PC: weight including tare after sampling and split, PLT 
concentration and WBC concentration. 
The measured data is presented in appendices 3 and 4 (marked with light pink background 
color). 
3.8.2 Calculations 
From the measured data, following quantities were calculated: 
 Volume of BC pool before sampling, 6BC PC before and after sampling, Intercept 
treated PC after sampling and split were calculated by the formula 1. The density of 
BC pool was estimated to be 1.04 g/ml [73] and the density of PC composed of 
approximately 30% of plasma and 70% of SSP+ storage solution to be 1.01 g/ml [74]. 
                       
                                                       
                    
 
  
 
    (1) 
 PLT content of BC pool before sampling, 6 BC PC before and after sampling, 
Intercept treated PC after sampling and split (including 7
th
 storage day analysis) were 
calculated by the formula 2. Also the WBC content of Intercept treated PC after 
sampling and split was calculated by the formula 2. 
                         
   
    
  
                     
   
  
                         
    
    (2) 
 Plasma content of 6BC PC was calculated by the formula 3. The corrected volume 290 
ml of SSP+ storage solution was used for calculations as approximately 10 ml was 
estimated to be lost in containers during production. 
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        (3) 
 Platelet recovery for 6BC PC production process, Intercept treatment process and 
storage were calculated by the formula 4. For 6BC PC production process the PLT 
content of BC pool before sampling and of 6BC PC before sampling were used. For 
Intercept treatment process the PLT content of 6BC PC after sampling and the PLT 
content together in both final PC doses after sampling and split were used. For platelet 
recovery of storage, the PLT content of the final product (Intercept treated PC after 
sampling and split) after production and on the last day of storage (7
th
 day) were used. 
                      
                                            
   
    
       
                                                  
   
    
 
     (4) 
 For the estimation of volume losses during Intercept treatment, the residual volume of 
PC left in PC storage container connected to amotosalen container, illumination bag, 
and CAD container, also the volume of Intercept treated PC before sampling and split 
were calculated using formula 1. The volume lost during sampling and splitting was 
calculated by the formula 5. 
                                         –                                     (5) 
The calculated values are presented in appendices 3 and 4 (marked with light green 
background color). 
3.8.3 Estimation of measurement uncertainties 
To assess the reliability of results obtained during the experimental work, the measurement 
uncertainty estimations are given both for directly measured and calculated quantities, as well 
as for other quantities used in calculations (SSP+ volume in BC pool, density of BC pool and 
PC). The explanations of obtaining the uncertainty estimates are given below and the 
numerical values of combined standard uncertainties (uc) and expanded uncertainties (U, k = 
2) are presented in appendix 5, table 11. 
The standard uncertainty of weight was taken from the calibration certificate (ATLM-
14/0303) of Sartorius BP8 scales issued by AS Metrosert  in April 2014. For the weight of 
tare, in addition to uncertainty from scales (1 g), also the difference between containers used 
in production and container used for measuring the weight of tare (resulting from variation in 
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container production, measuring the length of tubing, and sealing) were taken into account 
and estimated to be up to 2 g. The combined standard uncertainty that takes into account both 
uncertainty sources was calculated for the weight of tare by the formula 6. 
                       (6) 
The uncertainty of measurements obtained by hematology analyzer Sysmex (hematocrit, PLT 
concentration, WBC concentration) comprised of two sources: the uncertainty component 
accounting for random effects was calculated using routine laboratory quality control results 
for 2014 and the component accounting for systematic effects was calculated using inter-
laboratory comparison results for 2014. The calculations were done using the Nordtest 
approach [75]. The combined standard uncertainty was calculated using formula 6. 
For pH measurements, the uncertainty was calculated by the web application provided by 
Testing Centre of University of Tartu [76]. The highest uncertainty of individual results is 
presented and generalized to all pH measurements. 
For the SSP+ solution volume in BC pool two uncertainty sources were taken into account. 
The possible deviation of the initial volume in storage solution container from the indicated 
300 ml was estimated to be up to 3 ml. The maximum differences in SSP+ volume lost during 
production (residues left in SSP+ container, connected BC bags, and tubing), from the 10 ml 
that was taken into account in calculations, was also evaluated to be up to 3 ml. The combined 
standard uncertainty was calculated according to formula 6. 
To obtain uncertainty estimates for calculated results: volume, plasma content, PLT and WBC 
content in product, the ISO GUM modeling approach was used [77] and the uncertainty 
calculations were done by the Kragten spreadsheet method [78].  The formulas 1 - 3 were 
used as measurement models and the uncertainties of input quantities are presented in 
appendix 5, table 11. The uncertainty calculations were done for individual results and as the 
calculated uncertainty values differed to a small degree, the highest uncertainty is presented 
and generalized to all corresponding results. 
The expanded uncertainties were calculated by formula 7. The coverage factor k = 2 was 
used, giving the confidence level about 95%. 
                    (7) 
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4. Results and Discussion 
4.1 Buffy coat adjustment 
During the validation of separation process from July to November in 2013 the separation 
program settings for four MacoPress Smart separators for use with MacoPharma triple blood 
bag systems were adjusted. The goal was to optimize the separation process in order to 
achieve buffy coasts with as low volume and hematocrit as possible without hindering the 
quality of plasma and red blood cell suspension. The purpose for low volume and hematocrit 
was to obtain buffy coats suitable for the production of platelet concentrates that meet the 
requirements set for Intercept treatment. 
Prior to the changeover to MacoPress Smart separators, Dualpress separators (LMB 
Technologie GmbH) were used to separate the whole blood (collected into MacoPharma triple 
blood bag systems) into plasma, red blood cell suspension and buffy coat. In June 2013 the 
buffy coat volume was in range of 51 – 60 ml, with an average 56 ml and BC hematocrit was 
in range of 0.42 – 0.54, with an average 0.50 (the results of the regular quality control tests in 
June 2013 are presented in appendix 2, table 5). 
With that large volume and high hematocrit it was not possible to produce platelet 
concentrates that would meet the requirements set for Intercept treatment. The desired number 
of buffy coats used for production of double-dose platelet concentrate would be 7 or 8, but at 
least minimum 6 would be required. Therefore the maximum capacity of buffy coat bag (600 
ml) that would be used for pooling the buffy coats, set the restrictions for buffy coat volume 
(considering that 300 ml of SSP+ would be used). On the other hand, by diminishing the 
volume also lower hematocrit was required to meet the norm of plasma content. Hence, the 
reduction of buffy coat volume had to come from reduction of red blood cells while keeping 
the appropriate amount of plasma in buffy coat. 
In August 2014 the volume range of buffy coat was 47 – 52 ml, with an average 49 ml. The 
range for hematocrit was 0.35 – 0.51, with an average 0.41 (the results of the regular quality 
control tests in August 2014 are presented in appendix 2, table 6). These indicators were 
assessed to be suitable for production of platelet concentrates from 6 buffy coats, as the 
volume did not allow addition of no more. Further reduction of buffy coat volume was not 
possible without seriously compromising the quality of red blood cell suspension, as 
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minimizing the amount of red blood cells in buffy coat led to excess amount of white blood 
cells in red blood cell suspension. 
4.2 6BC platelet concentrate production 
The results for 6BC PC production are presented in appendix 3, table 7. The average, standard 
deviation, minimum, and maximum values are brought out separately for 6BC PC production 
validation, Intercept pathogen inactivation process validation, and for all 24 units together. 
The requirements for platelet concentrates acceptable for use with Intercept platelet 
processing set with dual storage containers are given in table 2. 
Table 2. PC acceptance criteria for Intercept treatment [64]. 
Platelet content Volume Plasma content RBC concentration 
2.5 – 7.0 x 1011 300 – 420 ml 
32 – 47 % < 4 x 106/ml 
7.1 – 8.0 x 1011 375 – 420 ml 
The platelet content of 6BC PC was in range of 469 – 714 x 109, with an average 555 x 109. 
The volume was in range of 362.4 – 394.1 ml, with an average 379.1 ml. All except one 6BC 
PC fell in platelet content range of 2.5 – 7.0 x 1011 and the corresponding volumes were in 
acceptable range 300 – 420 ml. The conformity to criteria held also when considering the 
expanded uncertainty for 6BC PC platelet content ± 14 x 109 and for volume ± 6.2 ml. Only 
one 6BC PC, with the highest platelet content 714 x 10
9
, was in range of 7.1 – 8.0 x 1011 and 
the corresponding volume was 375.2 ml. Both the platelet content and the volume fell in-
between the ranges as, when taking into account the uncertainty, the conformity to either one 
of the platelet content – volume ranges was possible. The possibility that platelet content and 
volume would fall in different ranges was considered relatively unlikely and not too relevant 
if both quantities would be close to changeover from one acceptability range to another. 
The plasma content of 6BC PC was in range of 34.6 – 37.6 %, with an average 36.2 %.  All 
6BC PC had acceptable plasma content also considering the expanded uncertainty ± 2.4 %. 
For 6BC PC products the conformity to the RBC concentration criteria was assessed by the 
visual inspection with the aid of colour chart provided for use with Intercept system. All 24 
6BC PC were with yellow or light orange color and considered to meet the criteria. 
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In addition, to evaluate the efficacy of the 6BC PC production process, the recovery of 
platelets was calculated. The results were in range of 71 – 92%, with an average 82%. While 
for other measured and calculated quantities, the average, standard deviation and range were 
similar for validation of 6BC PC production and validation of Intercept treatment process, so 
that the differences could be attributed to the normal variability of donor blood and 
production process, the difference for platelet recovery was outstandingly bigger. Though the 
average was quite alike (83% compared to 81%), the standard deviation and range were 
considerably bigger for validation of Intercept treatment (6.4% and 71 – 92% compared to 
2.3% and 77 – 87% for 6BC PC production validation). 
As the obtained platelet recovery values were not found to correlate with none of the 
characteristics of BC pool, the author of the thesis believes that the high variability of platelet 
recovery can be ascribed to the inconstancy of centrifuged BC pool separation process with 
manual presses, caused by the not well controlled duration of separation time, change in speed 
of flow during separation, and endpoint of separation. Whether the separation process of 
centrifuged pooled buffy coat could be more standardized using automatic blood separators 
and would it result in overall better recovery or not would need a further investigation. But 
despite of the high variability of platelet recovery, the validated 6BC PC production process 
was assessed to be overall performing well and fit for manufacturing platelet concentrates 
suitable for Intercept treatment. 
4.3 Intercept treatment process 
The data for 6BC PC treatment with Intercept double-dose system are presented in appendix 
4. In table 8 the results for the final platelet concentrate product (Intercept treated PC after 
sampling and split) are presented. The average, standard deviation, minimum, and maximum 
values are brought out separately for validation of Intercept treatment process, production 
after validation, and for all 38 processes. The results were assessed to be similar in two groups 
and the minor differences could be attributed to the normal variability of donor blood and 
production processes. The storage analysis are presented in table 9 and the volume losses 
during Intercept treatment process in table 10. 
The requirements from the legislation and the recommended quality parameters by the “Guide 
to the preparation, use and quality assurance of blood components” for pooled BC platelets in 
additive solution are given in table 3. 
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Table 3. Requirements and recommendations for pooled BC platelets in additive solution. 
Source of 
requirement/ 
recommendation 
Platelet 
content 
Volume WBC content pH (at the 
end of 
shelf-life) 
Quality 
requirements by 
legislation [59] 
As validated 
by the blood 
establishment 
Must assure 
the compliance 
with the pH 
requirement 
˂ 0.15 x 109 for 3BC PC 
(< 0.05 x 10
9
 per BC) 
 6.4 
Guide 
recommendations 
[12] 
 200 x 109  40 ml per 60 
x 10
9
 platelets 
˂ 0.3 x 109  6.4 
75% of 
conformity 
required 
- 
90% of conformity 
required 
- 
The platelet content of the final platelet concentrate at the end of production was in range of 
205 – 319 x 109, with an average 256 x 109. When taking into account the expanded 
uncertainty ± 10 x 109, 4 products could be below the limit and the conformity to platelet 
content requirement would be 95%. 
The 75% conformity to platelet content should be met also at the end of shelf life. The platelet 
recovery at storage was in range of 93 – 97% , with  an average 95%.  Applying the lowest 
(93%) recovery on all results and also considering the expanded uncertainty of the final 
product platelet content (± 10 x 109), 11  products were found to be at risk of falling below the 
limit by the time of expiry, making the conformity to platelet content requirement  86%. 
The volume of the final PC was in range of 163.4 – 189.1 ml, with an average 175.2 ml. The 
proper platelet content – volume ratio is needed to keep the optimal storage conditions for 
platelets. For 32 products the volume per platelet content was smaller than recommended, 6 
more could fall below the volume limit if the expanded uncertainty ± 5.2 ml was taken into 
account. As those were products with higher platelet content (majority of them had platelet 
content above the average, only three had slightly below), there was not much concern, even 
if the platelet loss during storage would be somewhat higher than on average. Out of 10 
platelet concentrates used for storage analysis, 4 had lower than recommended volume, but all 
of them had average or higher platelet recovery. Though storage analysis did not show lower 
platelet recovery for products that did not meet the volume criteria, the number of products 
analyzed was too small to make any firm assumptions whether the deviation from the 
recommended platelet content – volume ratio would result in somewhat higher platelet losses 
during storage. 
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To assess where and how much volume was lost during Intercept treatment process, the 
volume losses at different steps of the process were calculated. As expected, the amount and 
variability in losses was in accordance with the complexity of the container. Highest volume 
was lost in CAD container where platelet concentrate can stay in CAD or filter pouch 
(attached to the tubing for catching the smaller pieces in case of breakdown of CAD). Much 
less volume was lost in connected platelet concentrate storage container and amotosalen 
container, as well as during the sampling and splitting of Intercept treated PC. In routine work 
only a portion of products would be sampled, saving a few ml in most of the products in this 
step. As could be assumed, the volume that stayed in illumination container was relatively 
small compared to other processing steps. 
Some residues in containers are inevitable and the volume losses were quite constant in all the 
other steps except for CAD, for which not much can be done to minimize the volume lost, as 
the CAD container needs to be handled with extra care not to cause breakage. Looking at the 
calculated volume losses and based on visual assessment of residues left in discarded 
containers during processing, the handling of the system was evaluated to be sparing enough 
to avoid unnecessary volume losses. 
In addition to volume losses, the recovery of platelets during the Intercept treatment was 
calculated. The results were in range of 88 – 96 %, with an average 92%. The standard 
deviation over all results was 1.8% and similar for validation of Intercept treatment (1.5%) 
and production after validation (2.0%). 
All final PC products had less white blood cells than allowed (˂ 0.15 x 109). The results were 
in range of 0.016 – 0.054 x 109, with an average 0.027 x 109 in product. Even though the 
expanded uncertainty ± 0.086 x 109 was high compared to the results, it was acceptable to 
assess the conformity to criteria as all results were below the limit also when uncertainty was 
taken into account. 
The pH measurements on the day of production were in range of 6.88 – 7.09, with an average 
6.96.  On the last day of storage the pH of the product was in range of 6.99 – 7.05, with an 
average 7.01, being noticeably above the limit also when the expanded uncertainty ± 0.062 
was considered. 
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4.4 Production planning  
As the pathogen inactivation of platelet concentrates by Intercept system is a time-consuming 
multi-step process, requiring quite a lot of hands-on work, many aspects in addition to 
conformity to quality requirements need to be considered. 
First of all, the implementation of the process into routine production needs a thorough 
analysis in terms of staff planning and working hours. In NEMC Blood Centre the production 
of platelet concentrates starts in the afternoon (around 2 pm), after the initial processing 
(centrifugation, separation) of blood, collected the day before, has finished and the laboratory 
has conducted the mandatory testing. Due to the time limit of 6 – 16 hours for the CAD phase, 
the production of pathogen inactivated platelet concentrates could not be finished on the same 
day but was required to continue early next morning. Working in routine would require some 
of the staff to stay a bit longer and some of the staff to come earlier in the morning. The 
impact on the smooth operation of other production processes would need to be analyzed 
carefully, but most likely, despite of extra work, no additional staff would be needed and a 
carefully planned change of production arrangement would be enough. 
After proper validation and implementation of the Intercept process into routine production, 
the stability of production has to be assured as the changes in the first steps of processing can 
result in changes in BC composition, which can lead to nonconformity to requirements set for 
platelet concentrates to be treated with Intercept, influencing the pathogen inactivation 
capability of the system. Proper quality control program for routine production should include 
the assessment of stability of BC characteristics (volume, hematocrit) in addition to regular 
checks of BC pool as well as PC before and after pathogen inactivation, to assure the 
conformity to criteria, ensuring the process effectiveness. 
The most problematic aspect about implementing 100% pathogen inactivated platelet 
concentrate production would be the difficulty to plan the PC stock due to the prolonged 
production. Also currently, the maintenance of optimal PC stock (per blood group) is not an 
easy task due to the short shelf-life, relatively low issuing numbers (compared to red blood 
cell suspensions and plasma), and quite unstable demand (per blood group), resulting in 
relatively high outdating (compared to other blood products). But in the even more difficult 
planning situation, the added cost would put even more pressure to minimize the expiry. So 
the target outdating and measures to achieve it need to be put in place to avoid unnecessary 
waste of resources. 
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5. Summary 
The aim of this thesis was to develop a method for production of buffy coat platelet 
concentrates suitable for use with Intercept platelet processing set with dual-storage 
containers and to assess the conformity of pathogen inactivated platelet products with the 
required and recommended quality parameters. During the six month testing period, 
validations of 6BC PC production and subsequent processing with Intercept system were 
carried out, followed by the production and processing of limited number of platelet products 
after validations. 
In order to produce suitable platelet concentrates, the adjustment of whole blood separation 
process was necessary to find the compromise between the desired buffy coat parameters and 
the quality of plasma and red blood cell suspension. The succeeding production of platelet 
concentrates using 6 buffy coats proved the conformity to requirements for platelet content, 
volume, plasma content, and red blood cell concentration set for platelet concentrates suitable 
to be processed with Intercept system. 
After processing with Intercept system, the platelet and white blood cell content were 
assessed to be appropriate. A little concern was the lower than recommended amount of 
volume per platelet content in about half of the products, but as those were the units 
containing about average or higher platelet content and storage analysis showed good platelet 
recovery and normal pH values at the end of shelf life, the overall results for volume were 
also considered to be acceptable. 
Both the 6BC PC production and Intercept treatment process, as well as the storage of 
pathogen inactivated platelet products were evaluated to be efficient in terms of platelet 
recovery. Both the recovery results as well as the analysis of volume losses showed stability 
of handling the Intercept platelet processing system. Though the overall performance of 6BC 
PC production was showing adequate results, the high variability in platelet recovery shows 
an opportunity for further improvement and standardization of the platelet concentrate 
separation process. 
In conclusion, the testing of buffy coat platelet concentrate pathogen inactivation in NEMC 
Blood Centre can be considered successful, as the results show the readiness for routine 
production of pathogen inactivated buffy coat platelet concentrates and the experience gained 
gives confidence to overcome any obstructions either in processing or production planning. 
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6. Kokkuvõte 
Antud magistritöö eesmärgiks oli välja töötada tootmismeetod, mis võimaldaks valmistada 
buffy coat (BC) trombotsüütide kontsentraate, mis sobiksid töötlemiseks kahe säilituskotiga 
Intercept trombotsüütide patogeeninaktiveerimise süsteemiga ning vastaksid töötlemise 
järgselt kohustuslikele ning soovituslikele kvaliteedinõuetele. Kuue kuu pikkuse testperioodi 
jooksul teostati 6BC trombotsüütide kontsentraadi valmistamise valideerimine ja sellele 
järgnev Interceptiga töötlemise valideerimine ning valideerimisjärgselt toodeti limiteeritud arv 
patogeeninaktiveeritud trombotsüütide kontsentraate. 
Selleks, et sobivaid trombokontsentraate valmistada, oli eelnevalt vajalik modifitseerida 
täisvere separeerimisprotsessi, et leida kompromiss soovitud BC parameetrite ning plasma ja 
erütrotsüütide suspensiooni kvaliteedinäitajate vahel. Järgnev trombotsüütide kontsentraadi 
valmistamine kuuest BC-st tõestas, et saadud trombokontsentraadid vastavad tootja poolt 
kehtestatud trombotsüütide sisalduse, mahu, plasma sisalduse ja erütrotsüütide 
kontsentratsiooni kriteeriumitele ning sobivad seega töötlemiseks Intercept süsteemiga. 
Intercept patogeeninaktiveerimise süsteemiga töötlemise järgselt hinnati toote trombotsüütide 
ja leukotsüütide sisaldus sobivaks. Kuigi kõigis toodetes maht ei vastanud soovitatud 
nõuetele, hinnati see siiski sobivaks kuna antud toodetes oli trombotsüütide sisaldus pigem 
kõrgem kui keskmiselt ning säilivusanalüüsid näitasid häid tulemusi nii trombotsüütide 
sisalduse kui ka pH suhtes. 
Nii 6BC trombotsüütide kontsentraadi tootmise kui ka Intercept süsteemiga töötlemise 
protsess hinnati efektiivseks trombotsüütide saagise koha pealt. Võttes arvesse ka mahu kadu 
töötlemise erinevates etappides, hinnati Intercept süsteemi käsitlemine stabiilseks. Kuigi 
üleüldiselt hinnati 6BC trombotsüütide kontsentraadi tootmise protsessi käigus saadud 
tulemused heaks, leiti töö käigus saadud trombotsüütide saagise suurt varieeruvust 
analüüsides, et käsipressidega trombotsüütide kontsentraadi separeerimisprotsess ei ole hästi 
kontrollitav. Kas automaatsete separaatoritega oleks võimalik antud protsessi standardiseerida 
ning kas selle käigus oleks võimalik saavutada ka keskmiselt kõrgem trombotsüütide saagis, 
vajaks eraldi katsetamist. 
Kokkuvõttes võib hinnata BC trombotsüütide kontsentraadi patogeeninaktiveerimise testimist 
Intercept süsteemiga Põhja-Eesti Regionaalhaigla Verekeskuses edukaks kuna saadud 
tulemused näitavad valmisolekut antud protsessi juurutamiseks rutiintöösse.  
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Appendix 1 
Table 4. Weight of tare. 
Description of tare Weight of tare Picture of tare 
 
Tare BC pool before sampling 
 
BC (pool) bag including tube length 10 
cm + 10 cm + 20 cm. 
 
(MacoPharma, REF: 1MAMRT6281LU 
or 1MAMRT6280LU) 
 
 
 
 
28 g 
 
 
Tare 6BC PC before sampling 
 
PC storage container including sampling 
pouch and tube length 10 cm. 
 
(Fenwal, REF: 1FE00R7041) 
 
 
 
 
 
56 g 
 
 
Tare 6BC PC after sampling 
 
PC storage container including tube 
length 10 cm. 
 
(Fenwal, REF: 1FE00R7041) 
 
 
 
 
 
39 g 
 
 
Tare PC storage container with 
amotosalen container 
 
PC storage container + amotosalen 
container (the weight of amotosalen 
solution subtracted) including tube length 
12 cm (between containers) + 46 cm  
 
(Fenwal, REF: 1FE00R7041; 
Cerus, REF: OCEINT2503) 
 
 
52 g 
 
49 
 
Description of tare Weight of tare Picture of tare 
 
Tare illumination bag 
 
Illumination bag with tube length 4 cm + 
14 cm. 
 
 
(Cerus, REF: OCEINT2503) 
 
 
 
 
32 g 
 
 
Tare CAD container 
 
CAD bag and filter pouch, with tube 
length 4 cm. 
 
 
(Cerus, REF: OCEINT2503) 
 
 
 
 
52 g 
 
 
Tare Intercept treated PC before 
sampling and split 
 
Two connected PC storage containers 
including two sampling pouches. 
 
(Cerus, REF: OCEINT2503) 
 
 
 
 
93 g 
 
 
Tare of final product: Intercept treated 
PC after sampling and split 
 
PC storage container including tube 
length 10 cm. 
 
(Cerus, REF: OCEINT2503) 
 
 
 
 
42 g 
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Appendix 2 
Table 5. Quality control results for buffy coats in June 2013. 
Analysis 
number 
Date 
 
Blood nr 
H050013 
Volume of 
BC (ml) 
Hct of BC 
 
Platelet content 
(10
9
/1BC) 
1 4.06.2013 009927 56 0.51 71 
2 4.06.2013 010906 59 0.50 117 
3 4.06.2013 013719 58 0.49 122 
4 5.06.2013 010100 55 0.48 106 
5 5.06.2013 010891 55 0.49 128 
6 5.06.2013 013656 59 0.54 91 
7 6.06.2013 009996 57 0.50 126 
8 6.06.2013 010879 57 0.50 123 
9 6.06.2013 013686 57 0.52 77 
10 7.06.2013 010392 51 0.50 107 
11 7.06.2013 010958 53 0.49 103 
12 7.06.2013 011725 58 0.50 119 
13 11.06.2013 010600 55 0.42 118 
14 11.06.2013 011020 55 0.49 107 
15 11.06.2013 011704 58 0.52 93 
16 12.06.2013 010362 55 0.50 77 
17 12.06.2013 011032 56 0.50 101 
18 12.06.2013 011677 55 0.48 67 
19 13.06.2013 010344 53 0.49 94 
20 13.06.2013 010833 51 0.48 99 
21 13.06.2013 011746 55 0.53 96 
22 14.06.2013 011270 55 0.48 119 
23 14.06.2013 013812 55 0.49 96 
24 14.06.2013 014527 56 0.54 133 
25 18.06.2013 010544 53 0.51 72 
26 18.06.2013 011124 60 0.51 97 
27 18.06.2013 013937 57 0.51 48 
28 19.06.2013 010273 58 0.48 121 
29 19.06.2013 011128 56 0.49 126 
30 19.06.2013 013859 59 0.51 84 
31 20.06.2013 011200 57 0.50 158 
32 20.06.2013 011271 59 0.51 99 
33 20.06.2013 013990 58 0.51 92 
34 21.06.2013 010323 59 0.50 93 
35 21.06.2013 011145 51 0.51 97 
36 21.06.2013 014001 60 0.50 115 
37 26.06.2013 014199 52 0.51 138 
38 26.06.2013 014614 58 0.49 88 
39 27.06.2013 014108 51 0.53 98 
40 27.06.2013 014713 60 0.51 127 
41 28.06.2013 014893 57 0.50 102 
42 28.06.2013 015219 57 0.43 110 
Average 56 0.50 104 
Minimum 51 0.42 48 
Maximum 60 0.54 158 
Standard deviation 2.6 0.023 21 
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Table 6. Quality control results for buffy coats in August 2014. 
Analysis 
number 
Date 
 
Blood nr 
H050014 
Volume of 
BC (ml) 
Hct of BC 
 
Platelet content 
(10
9
/1BC) 
1 1.08.2014 019143 49 0.45 100 
2 1.08.2014 020030 50 0.40 125 
3 5.08.2014 019558 49 0.35 130 
4 5.08.2014 021137 51 0.43 147 
5 6.08.2014 019036 48 0.38 122 
6 6.08.2014 021172 51 0.51 75 
7 7.08.2014 019051 48 0.43 71 
8 7.08.2014 020105 48 0.37 105 
9 8.08.2014 019631 50 0.37 116 
10 8.08.2014 020150 49 0.43 146 
11 12.08.2014 017969 48 0.41 94 
12 12.08.2014 019080 50 0.40 109 
13 12.08.2014 020246 50 0.41 150 
14 13.08.2014 019097 50 0.38 124 
15 13.08.2014 020327 49 0.46 116 
16 13.08.2014 022016 51 0.38 100 
17 14.08.2014 018435 48 0.42 145 
18 14.08.2014 019339 52 0.48 116 
19 14.08.2014 020348 48 0.48 75 
20 15.08.2014 019360 52 0.40 100 
21 15.08.2014 020299 52 0.48 102 
22 15.08.2014 021501 51 0.42 93 
23 19.08.2014 019801 50 0.40 95 
24 19.08.2014 020419 47 0.42 110 
25 19.08.2014 021547 48 0.39 144 
26 22.08.2014 019440 47 0.39 112 
27 22.08.2014 021255 47 0.41 113 
28 22.08.2014 021677 51 0.39 108 
29 26.08.2014 019791 49 0.39 118 
30 26.08.2014 020499 49 0.43 75 
31 26.08.2014 021706 49 0.38 87 
32 27.08.2014 019836 48 0.37 112 
33 27.08.2014 021296 51 0.41 96 
34 27.08.2014 021755 51 0.45 125 
35 28.08.2014 019932 49 0.38 121 
36 28.08.2014 020539 51 0.46 138 
37 28.08.2014 021784 49 0.38 151 
38 29.08.2014 019858 49 0.45 127 
39 29.08.2014 020626 48 0.40 113 
40 29.08.2014 022128 49 0.43 163 
Average 49 0.41 114 
Minimum 47 0.35 71 
Maximum 52 0.51 163 
Standard deviation 1.4 0.037 23 
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Appendix 3 
Table 7. Data of 6BC PC production (d – density, rec – recovery, u – unit, W - weight). 
Validation of 6BC PC production 
Product 
Date of 
production 
BC pool before sampling (tare 28 g, d = 1.04 g/ml) 6BC PC before sampling (tare 56 g, d =1.01 g/ml) 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
3
/µl) 
PLT 
(10
9
/u) 
Hct 
 
Plasma 
(%) 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
3
/µl) 
PLT 
(10
9
/u) 
PLT rec 
(%) 
RBC  
(visual) 
6BC-PC-1 24.09.14 614 563.5 1096 618 0.184 36.9 454 394.1 1260 497 80 ok 
6BC-PC-2 24.09.14 628 576.9 1013 584 0.202 37.0 438 378.2 1243 470 80 ok 
6BC-PC-3 25.09.14 610 559.6 1174 657 0.182 36.6 444 384.2 1426 548 83 ok 
6BC-PC-4 25.09.14 617 566.3 1047 593 0.203 35.8 434 374.3 1279 479 81 ok 
6BC-PC-5 30.09.14 603 552.9 1051 581 0.174 36.5 445 385.1 1247 480 83 ok 
6BC-PC-6 30.09.14 608 557.7 1237 690 0.189 35.9 433 373.3 1500 560 81 ok 
6BC-PC-7 1.10.14 626 575.0 1015 584 0.192 37.6 452 392.1 1197 469 80 ok 
6BC-PC-8 1.10.14 618 567.3 1188 674 0.189 37.0 448 388.1 1421 552 82 ok 
6BC-PC-9 2.10.14 609 558.7 1319 737 0.200 35.1 429 369.3 1580 584 79 ok 
6BC-PC-10 7.10.14 612 561.5 1341 753 0.185 36.6 441 381.2 1627 620 82 ok 
6BC-PC-11 9.10.14 607 556.7 1657 923 0.190 35.7 435 375.2 1904 714 77 ok 
6BC-PC-12 9.10.14 615 564.4 1374 776 0.201 35.7 437 377.2 1782 672 87 ok 
Average 614 563.4 1209 681 0.191 36.4 441 381.0 1456 554 81 - 
Minimum 603 552.9 1013 581 0.174 35.1 429 369.3 1197 469 77 - 
Maximum 628 576.9 1657 923 0.203 37.6 454 394.1 1904 714 87 - 
Standard deviation 7.5 7.2 191 103 0.0091 0.73 7.9 7.8 230 82 2.3 - 
Validation of 6BC PC pathogen inactivation with Intercept double-dose system 
6BC-PC-INT-1 22.10.14 622 571.2 1176 672 0.197 36.8 446 386.1 1355 523 78 ok 
6BC-PC-INT-2 22.10.14 617 566.3 1002 567 0.201 35.9 441 381.2 1280 488 86 ok 
6BC-PC-INT-3 29.10.14 610 559.6 1235 691 0.190 36.0 429 369.3 1523 562 81 ok 
6BC-PC-INT-4 29.10.14 609 558.7 1105 617 0.197 35.4 439 379.2 1465 556 90 ok 
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Product 
Date of 
production and 
analysis 
BC pool before sampling (tare 28 g, d = 1.04 g/ml) 6BC PC before sampling (tare 56 g, d =1.01 g/ml) 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
3
/µl) 
PLT 
(10
9
/u) 
Hct 
 
Plasma 
(%) 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
3
/µl) 
PLT 
(10
9
/u) 
PLT rec 
(%) 
RBC  
(visual) 
6BC-PC-INT-5 5.11.14 621 570.2 1422 811 0.194 36.9 437 377.2 1520 573 71 ok 
6BC-PC-INT-6 5.11.14 606 555.8 1365 759 0.190 35.6 441 381.2 1630 621 82 ok 
6BC-PC-INT-7 6.11.14 622 571.2 1096 626 0.205 36.1 432 372.3 1283 478 76 ok 
6BC-PC-INT-8 6.11.14 614 563.5 1045 589 0.199 35.7 442 382.2 1246 476 81 ok 
6BC-PC-INT-9 12.11.14 624 573.1 1323 758 0.209 36.0 438 378.2 1800 681 90 ok 
6BC-PC-INT-10 12.11.14 619 568.3 1162 660 0.220 34.6 422 362.4 1609 583 88 ok 
6BC-PC-INT-11 13.11.14 617 566.3 1021 578 0.189 36.9 437 377.2 1411 532 92 ok 
6BC-PC-INT-12 13.11.14 617 566.3 1249 707 0.185 37.2 440 380.2 1568 596 84 ok 
Average 617 565.9 1183 670 0.198 36.1 437 377.2 1474 556 83 - 
Minimum 606 555.8 1002 567 0.185 34.6 422 362.4 1246 476 71 - 
Maximum 624 573.1 1422 811 0.220 37.2 446 386.1 1800 681 92 - 
Standard deviation 5.7 5.5 138 78 0.0098 0.75 6.5 6.4 167 61 6.4 - 
Results of all 24 units of 6BC PC 
Average 615 564.6 1196 675 0.195 36.2 439 379.1 1465 555 82 - 
Minimum 603 552.9 1002 567 0.174 34.6 422 362.4 1197 469 71 - 
Maximum 628 576.9 1657 923 0.220 37.6 454 394.1 1904 714 92 - 
Standard deviation 6.6 6.4 163 90 0.0099 0.74 7.3 7.3 197 71 4.8 - 
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Appendix 4 
Table 8. Data of 6BC PC Intercept treatment process (d – density, rec – recovery, u – unit, W - weight). 
Validation of 6BC PC pathogen inactivation with Intercept double-dose system 
Product 
Date of 
production 
6BC PC after sampling (tare 39 g, d = 1.01 g/ml) Intercept treated PC after sampling and split (tare 42 g, d = 1.01 g/ml) 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
3
/µl) 
PLT 
(10
9
/u) 
PLT 
(10
3
/µl) 
WBC 
(10
3
/µl) 
Dose 
 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
9
/u) 
WBC 
(10
9
/u) 
PLT rec 
(%) 
pH 
 
6BC-PC-INT-1 22. - 23.10.14 426 383.2 1355 519 1365 0.1 
1 211 167.3 228 0.017 
91 6.90 2 223 179.2 245 0.018 
6BC-PC-INT-2 22. - 23.10.14 421 378.2 1280 484 1258 0.2 
1 220 176.2 222 0.035 
91 6.90 2 218 174.3 219 0.035 
6BC-PC-INT-3 29. - 30.10.14 409 366.3 1523 558 1503 0.1 
1 207 163.4 246 0.016 
90 6.88 2 216 172.3 259 0.017 
6BC-PC-INT-4 29. - 30.10.14 419 376.2 1465 551 1457 0.2 
1 218 174.3 254 0.035 
92 6.94 2 218 174.3 254 0.035 
6BC-PC-INT-5 05. - 06.11.14 417 374.3 1520 569 1552 0.2 
1 218 174.3 270 0.035 
93 6.94 2 210 166.3 258 0.033 
6BC-PC-INT-6 05. - 06.11.14 421 378.2 1630 616 1650 0.2 
1 215 171.3 283 0.034 
93 6.90 2 221 177.2 292 0.035 
6BC-PC-INT-7 06. - 07.11.14 412 369.3 1283 474 1257 0.1 
1 216 172.3 217 0.017 
90 7.05 2 211 167.3 210 0.017 
6BC-PC-INT-8 06. - 07.11.14 423 380.2 1246 474 1196 0.1 
1 215 171.3 205 0.017 
88 7.09 2 222 178.2 213 0.018 
6BC-PC-INT-9 12. - 13.11.14 418 375.2 1800 675 1801 0.1 
1 221 177.2 319 0.018 
93 6.91 2 215 171.3 308 0.017 
6BC-PC-INT-10 12. - 13.11.14 402 359.4 1609 578 1602 0.2 
1 210 166.3 266 0.033 
92 6.95 2 211 167.3 268 0.033 
6BC-PC-INT-11 13. - 14.11.14 417 374.3 1411 528 1364 0.1 
1 216 172.3 235 0.017 
91 7.09 2 222 178.2 243 0.018 
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Product 
Date of 
production 
6BC PC after sampling (tare 39 g, d = 1,01) Intercept treated PC after sampling and split (tare 42 g, d = 1,01 g/ml) 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
3
/µl) 
PLT 
(10
9
/u) 
PLT 
(10
3
/µl) 
WBC 
(10
3
/µl) 
Dose 
 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
9
/u) 
WBC 
(10
9
/u) 
PLT rec 
(%) 
pH 
 
6BC-PC-INT-12 13. - 14.11.14 422 379.2 1568 595 1568 0.1 
1 223 179.2 281 0.018 
91 6.91 2 209 165.3 259 0.017 
Average 417 374.5 1474 552 1464 0.14 - 216 172.4 252 0.024 91 6.96 
Minimum 402 359.4 1246 474 1196 0.1 - 207 163.4 205 0.016 88 6.88 
Maximum 426 383.2 1800 675 1801 0.2 - 223 179.2 319 0.035 93 7.09 
Standard deviation 6.7 6.6 167 61 182 0.051 - 4.8 4.8 31 0.0087 1.5 0.077 
Production after validation 
H050014227109 14. - 15.01.15 420 377.2 1484 560 1495 0.1 
1 216 172.3 258 0.017 
93 - 2 218 174.3 261 0.017 
H050014227110 14. - 15.01.15 422 379.2 1476 560 1432 0.1 
1 220 176.2 252 0.018 
91 - 2 224 180.2 258 0.018 
H050014227111 15. - 16.01.15 414 371.3 1369 508 1359 0.1 
1 224 180.2 245 0.018 
93 - 2 210 166.3 226 0.017 
H050014227112 15. - 16.01.15 421 378.2 1655 626 1649 0.2 
1 219 175.2 289 0.035 
92 - 2 218 174.3 287 0.035 
H050014227191 22. - 23.01.15 415 372.3 1703 634 1611 0.1 
1 212 168.3 271 0.017 
88 - 2 223 179.2 289 0.018 
H050014227192 22. - 23.01.15 438 395.0 1722 680 1721 0.2 
1 226 182.2 314 0.036 
92 - 2 227 183.2 315 0.037 
H050015200031 27. - 28.01.15 423 380.2 1652 628 1603 0.3 
1 225 181.2 290 0.054 
91 - 2 221 177.2 284 0.053 
H050015200032 27. - 28.01.15 421 378.2 1375 520 1350 0.2 
1 224 180.2 243 0.036 
94 - 2 226 182.2 246 0.036 
H050015200048 28. - 29.01.15 429 386.1 1151 444 1135 0.2 
1 225 181.2 206 0.036 
92 - 2 224 180.2 205 0.036 
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Product 
Date of 
production 
6BC PC after sampling (tare 39 g, d = 1.01 g/ml) Intercept treated PC after sampling and split (tare 42 g, d = 1.01 g/ml) 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
3
/µl) 
PLT 
(10
9
/u) 
PLT 
(10
3
/µl) 
WBC 
(10
3
/µl) 
Dose 
 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
9
/u) 
WBC 
(10
9
/u) 
PLT rec 
(%) 
pH 
 
H050015200049 28. - 29.01.15 419 376.2 1379 519 1318 0.2 
1 219 175.2 231 0.035 
88 - 2 216 172.3 227 0.034 
H050015200114 03. - 04.02.15 418 375.2 1654 621 1595 0.3 
1 215 171.3 273 0.051 
89 - 2 219 175.2 280 0.053 
H050015200122 04. - 05.02.15 433 390.1 1511 589 1487 0.1 
1 223 179.2 266 0.018 
91 - 2 225 181.2 269 0.018 
H050015200123 04. - 05.02.15 423 380.2 1381 525 1345 0.1 
1 222 178.2 240 0.018 
90 - 2 218 174.3 234 0.017 
H050015200134 05. - 06.02.15 424 381.2 1702 649 1622 0.1 
1 223 179.2 291 0.018 
89 - 2 221 177.2 287 0.018 
H050015200135 05. - 06.02.15 418 375.2 1373 515 1329 0.1 
1 218 174.3 232 0.017 
91 - 2 221 177.2 236 0.018 
H050015200166 10. - 11.02.15 418 375.2 1504 564 1502 0.1 
1 225 181.2 272 0.018 
96 - 2 223 179.2 269 0.018 
H050015200169 11. - 12.02.15 412 369.3 1382 510 1318 0.2 
1 212 168.3 222 0.034 
88 - 2 216 172.3 227 0.034 
H050015200170 11. - 12.02.15 423 380.2 1464 557 1442 0.2 
1 228 184.2 266 0.037 
94 - 2 223 179.2 258 0.036 
H050015200181 12. - 13.02.15 405 362.4 1431 519 1363 0.2 
1 218 174.3 238 0.035 
92 - 2 220 176.2 240 0.035 
H050015200182 12. - 13.02.15 409 366.3 1362 499 1373 0.2 
1 213 169.3 232 0.034 
93 - 2 214 170.3 234 0.034 
H050015200223 17. - 18.02.15 427 384.2 1635 628 1633 0.2 
1 225 181.2 296 0.036 
93 - 2 221 177.2 289 0.035 
H050015200224 17. - 18.02.15 418 375.2 1647 618 1589 0.2 
1 217 173.3 275 0.035 
90 - 2 221 177.2 282 0.035 
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Product 
Date of 
production 
6BC PC after sampling (tare 39 g, d = 1.01) Intercept treated PC after sampling and split (tare 42 g, d = 1.01 g/ml) 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
3
/µl) 
PLT 
(10
9
/u) 
PLT 
(10
3
/µl) 
WBC 
(10
3
/µl) 
Dose 
 
W incl tare 
(g) 
Volume 
(ml) 
PLT 
(10
9
/u) 
WBC 
(10
9
/u) 
PLT rec 
(%) 
pH 
 
H050015200231 18. - 19.02.15 430 387.1 1569 607 1512 0.1 
1 227 183.2 277 0.018 
93 - 2 233 189.1 286 0.019 
H050015200232 18. - 19.02.15 403 360.4 1504 542 1453 0.2 
1 215 171.3 249 0.034 
92 - 2 215 171.3 249 0.034 
H050015200240 19. - 20.02.15 412 369.3 1493 551 1446 0.1 
1 213 169.3 245 0.017 
90 - 2 216 172.3 249 0.017 
H050015200281 26. - 27.02.15 419 376.2 1293 486 1281 0.1 
1 221 177.2 227 0.018 
93 - 2 219 175.2 224 0.018 
Average 420 377.0 1495 564 1460 0.16 - 220 176.6 258 0.029 92 - 
Minimum 403 360.4 1151 444 1135 0.1 - 210 166.3 205 0.017 88 - 
Maximum 438 395.0 1722 680 1721 0.3 - 233 189.1 315 0.054 96 - 
Standard deviation 8.0 8.0 145 59 141 0.064 - 4.8 4.8 27 0.011 2.0 - 
All units together 
Average 419 376.2 1488 560 1461 0.16 - 219 175.2 256 0.027 92 - 
Minimum 402 359.4 1151 444 1135 0.1 - 207 163.4 205 0.016 88 - 
Maximum 438 395.0 1800 680 1801 0.3 - 233 189.1 319 0.054 96 - 
Standard deviation 7.6 7.6 151 59 152 0.060 - 5.2 5.1 28 0.011 1.8 - 
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Table 9. Data of storage analysis (d – density, rec – recovery, u - unit). 
Product Dose 
Volume 
(ml) 
After production, 1st storage day (d = 1.01 g/ml) 7th storage day (d = 1.01 g/ml) 
Date 
 
PLT 
(10
3
/µl) 
PLT 
(10
9
/u) 
pH 
 
Date 
 
PLT 
(10
3
/µl) 
PLT  
(10
9
/u) 
pH 
 
PLT rec 
(%) 
6BC-PC-INT-1 
1 167.3 
23.10.14 1365 
228 
6.90 29.10.14 
1288 215 7.00 94 
2 179.2 245 1271 228 7.00 93 
6BC-PC-INT-2 
1 176.2 
23.10.14 1258 
222 
6.90 29.10.14 
1183 208 7.00 94 
2 174.3 219 1214 212 7.00 97 
6BC-PC-INT-3 
1 163.4 
30.10.14 1503 
246 
6.88 05.11.14 
1427 233 7.00 95 
2 172.3 259 1432 247 7.02 95 
6BC-PC-INT-4 
1 174.3 
30.10.14 1457 
254 
6.94 05.11.14 
1387 242 6.99 95 
2 174.3 254 1407 245 7.00 97 
6BC-PC-INT-5 
1 174.3 
06.11.14 1552 
270 
6.94 12.11.14 
1504 262 7.05 97 
2 166.3 258 1478 246 7.05 95 
Average 172.2 - 1427 245 6.91 - 1359 234 7.01 95 
Minimum 163.4 - 1258 219 6.88 - 1183 208 6.99 93 
Maximum 179.2 - 1552 270 6.94 - 1504 262 7.05 97 
Standard deviation 4.9 - 117 17 0.027 - 112 18 0.022 1.2 
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Table 10. Data of volume losses during Intercept treatment (d – density, W – weight). 
Product 
PC storage container + 
amotosalen bag (tare 52 g, 
d = 1.01 g/ml) 
Illumination bag (tare 
32 g, d = 1.01 g/ml) 
 
CAD container (tare 52 g, 
d = 1.01 g/ml) 
 
Final product before 
sampling and split (tare 
93 g, d = 1.01 g/ml) 
Final product after split 
Lost at 
split Dose 1 Dose 2 
W incl tare 
 (g) 
Volume 
(ml) 
W incl tare  
(g) 
Volume 
(ml) 
W incl tare 
(g) 
Volume 
(ml) 
W incl tare  
(g) 
Volume 
(ml) 
Volume 
(ml) 
Volume 
(ml) 
Volume 
(ml) 
6BC-PC-INT-1 59 6.9 36 4.0 84 31.7 451 354.5 167.3 179.2 8.0 
6BC-PC-INT-2 60 7.9 35 3.0 85 32.7 455 358.4 176.2 174.3 7.9 
6BC-PC-INT-3 60 7.9 35 3.0 82 29.7 441 344.6 163.4 172.3 8.9 
6BC-PC-INT-4 60 7.9 35 3.0 79 26.7 454 357.4 174.3 174.3 8.8 
6BC-PC-INT-5 60 7.9 35 3.0 85 32.7 446 349.5 174.3 166.3 8.9 
6BC-PC-INT-6 60 7.9 34 2.0 82 29.7 455 358.4 171.3 177.2 9.9 
6BC-PC-INT-7 60 7.9 35 3.0 81 28.7 445 348.5 172.3 167.3 8.9 
6BC-PC-INT-8 62 9.9 35 3.0 81 28.7 454 357.4 171.3 178.2 7.9 
6BC-PC-INT-9 59 6.9 34 2.0 80 27.7 453 356.4 177.2 171.3 7.9 
6BC-PC-INT-10 60 7.9 36 4.0 77 24.8 436 339.6 166.3 167.3 6.0 
6BC-PC-INT-11 59 6.9 35 3.0 76 23.8 455 358.4 172.3 178.2 7.9 
6BC-PC-INT-12 59 6.9 35 3.0 85 32.7 450 353.5 179.2 165.3 9.0 
Average 60 7.8 35 3.0 81 29.1 450 353.1 172.1 172.6 8.3 
Minimum 59 6.9 34 2.0 76 23.8 436 339.6 163.4 165.3 6.0 
Maximum 62 9.9 36 4.0 85 32.7 455 358.4 179.2 179.2 9.9 
Standard deviation 0.83 0.83 0.60 0.60 3.1 3.0 6.3 6.2 4.6 5.1 1.0 
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Appendix 5 
Table 11. Uncertainty estimations. 
 Combined 
standard 
uncertainty uc 
Expanded 
uncertainty U 
 (k = 2) 
Uncertainty components used for 
calculating uc 
Measurements 
Weight 1.0 g - u(scales) = 1 g 
Weight of tare 2.2 g - u(scales) = 1 g 
u(variation between containers) = 2 g 
Hematocrit 0.0060 - u(routine quality control) = 0.0024 
u(interlaboratory comparison) = 0.0055 
PLT concentration 9.5 x 10
3
/µl - u(routine quality control) = 5.8 x 10
3
/µl 
u(interlaboratory comparison) = 7.5 x 10
3
/µl 
WBC concentration 0.24 x 10
3
/µl - u(routine quality control) = 0.087 x 10
3
/µl 
u(interlaboratory comparison) = 0.22 x 10
3
/µl 
pH 0.031 0.062 (calculations done by web application) 
Quantities used for calculation 
Density of BC pool 0.005 g/ml - u(variation of composition) = 0.005 g/ml 
Density of PC 0.005 g/ml - u(variation of composition) = 0.005 g/ml 
Volume of SSP+ solution 
in BC pool 
4.2 ml - u(variation of initial volume) = 3 ml 
u(variation of lost volume) = 3 ml 
Calculated results 
Volume of BC pool 
(before sampling) 
3.6 ml - uc(weight) 
uc(weight of tare) 
uc(density of BC pool) 
Volume of 6BC PC 
(before sampling) 
3.1 ml 6.2 ml uc(weight) 
uc(weight of tare) 
uc(density of PC) 
Volume of Intercept 
treated PC (after 
sampling and split) 
2.6 ml 5.2 ml uc(weight) 
uc(weight of tare) 
uc(density of PC) 
Plasma content of  
6BC PC 
1.2 % 2.4 % uc(hematocrit) 
uc(volume of BC pool) 
uc(volume of SSP+ solution in BC pool) 
PLT content of 6BC PC 
(before sampling) 
6.9 x 10
9
/unit 14 x 10
9
/unit uc(PLT concentration) 
uc(volume of 6BC PC) 
PLT content of Intercept 
treated PC (after 
sampling and split) 
5.0 x 10
9
/unit 10 x 10
9
/unit uc(PLT concentration) 
uc(volume of Intercept treated PC) 
WBC content of 
Intercept treated PC 
(after sampling and 
split) 
0.043 x 10
9
/unit 0.086 x 10
9
/unit uc(WBC concentration) 
uc(volume of Intercept treated PC) 
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